Browse result page of CancerPDF Database
Please click on CancerPDF_ID for detailed information about peptide.
CancerPDF_ID | Peptide seq | Protein Name | Fluid | Mass/Z | Profiling Technique | Cancer Type | Expression Regulation | PUBMED ID |
---|---|---|---|---|---|---|---|---|
CancerPDF_ID1 | LAEGGGVR | Fibrinogen alpha chain | Serum | 758.45 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
CancerPDF_ID2 | FLAEGGGVR | Fibrinogen alpha chain | Serum | 905.5 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
CancerPDF_ID3 | DFLAEGGGVR | Fibrinogen alpha chain | Serum | 1020.47 | MALDI-TOF | Metastatic thyroid carcinomas | Differentially expressed between cancer vs normal samples | 16896061 |
CancerPDF_ID23 | HWESASLL | Complement C3f | Serum | 942.44 | MALDI-TOF | Metastatic thyroid carcinomas | Differentially expressed between cancer vs normal samples | 16896061 |
CancerPDF_ID24 | IHWESASLL | Complement C3f | Serum | 1055.6 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
CancerPDF_ID25 | RIHWESASLL | Complement C3f | Serum | 1211.7 | MALDI-TOF | Metastatic thyroid carcinomas | Differentially expressed between cancer vs normal samples | 16896061 |
CancerPDF_ID45 | PDGDFNSYVR | Complement C4 precursor | Serum | 585.23 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
CancerPDF_ID46 | HAAYHPF | Inter-alpha-trypsin inhibitor heavy chain H4 | Serum | 842.4 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
CancerPDF_ID58 | HAAYHPFR | Inter-alpha-trypsin inhibitor heavy chain H16 | Serum | 998.45 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
CancerPDF_ID88 | HFFFPK | CLUSTERIN precursor | Serum | 822.41 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
CancerPDF_ID89 | HFFFPKSRIV | CLUSTERIN precursor | Serum | 1277.71 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
CancerPDF_ID91 | RPPGFSPF | Bradykinin (and des-Arg bradykinin) | Serum | 904.48 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
CancerPDF_ID92 | RPPGFSPFR | Bradykinin (and des-Arg bradykinin) | Serum | 1060.57 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
CancerPDF_ID104 | YVGKKQL | Haptoglobin precursor | Plasma | NA | MALDI-TOF | Normal | NA | 17269714 |
CancerPDF_ID105 | VQKTIAEN | Haptoglobin precursor | Plasma | NA | MALDI-TOF | Normal | NA | 17269714 |
CancerPDF_ID106 | GRNANFKF | Haptoglobin precursor | Plasma | NA | MALDI-TOF | Normal | NA | 17269714 |
CancerPDF_ID107 | YTLNNEKQ | Haptoglobin precursor | Plasma | NA | MALDI-TOF | Normal | NA | 17269714 |
CancerPDF_ID108 | YAEVGRVGY | Haptoglobin precursor | Plasma | NA | MALDI-TOF | Normal | NA | 17269714 |
CancerPDF_ID109 | KFTDHLKY | Haptoglobin precursor | Plasma | NA | MALDI-TOF | Normal | NA | 17269714 |
CancerPDF_ID110 | YVGKKQLVE | Haptoglobin precursor | Plasma | NA | MALDI-TOF | Normal | NA | 17269714 |
CancerPDF_ID111 | WVQKTIAEN | Haptoglobin precursor | Plasma | NA | MALDI-TOF | Normal | NA | 17269714 |
CancerPDF_ID112 | FAVHDLEEDT | Haptoglobin precursor | Plasma | NA | MALDI-TOF | Normal | NA | 17269714 |
CancerPDF_ID113 | FKFTDHLKY | Haptoglobin precursor | Plasma | NA | MALDI-TOF | Normal | NA | 17269714 |
CancerPDF_ID114 | AVHDLEEDTW | Haptoglobin precursor | Plasma | NA | MALDI-TOF | Normal | NA | 17269714 |
CancerPDF_ID120 | KIRPFFPQQ | Fibrinogen beta chain | Plasma | NA | MALDI-TOF | Normal | NA | 17269714 |
CancerPDF_ID121 | FTSHNGMQ | Fibrinogen gamma chain | Plasma | NA | MALDI-TOF | Normal | NA | 17269714 |
CancerPDF_ID124 | GKQLNLKL | Apolipoprotein A-I | Plasma | NA | MALDI-TOF | Normal | NA | 17269714 |
CancerPDF_ID125 | YTKKLNTQ | Apolipoprotein A-I | Plasma | NA | MALDI-TOF | Normal | NA | 17269714 |
CancerPDF_ID126 | EEYTKKLNTQ | Apolipoprotein A-I | Plasma | NA | MALDI-TOF | Normal | NA | 17269714 |
CancerPDF_ID128 | ISRIKQSEL | Apolipoprotein C-I | Plasma | NA | MALDI-TOF | Normal | NA | 17269714 |
CancerPDF_ID130 | SQVAQQARG | Apolipoprotein C-III | Plasma | NA | MALDI-TOF | Normal | NA | 17269714 |
CancerPDF_ID131 | ESQVAQQARG | Apolipoprotein C-III | Plasma | NA | MALDI-TOF | Normal | NA | 17269714 |
CancerPDF_ID136 | FSSPHGKDLL | Transferrin | Plasma | NA | MALDI-TOF | Normal | NA | 17269714 |
CancerPDF_ID137 | FRSETKDLL | Transferrin | Plasma | NA | MALDI-TOF | Normal | NA | 17269714 |
CancerPDF_ID138 | VKHSTIFENL | Transferrin | Plasma | NA | MALDI-TOF | Normal | NA | 17269714 |
CancerPDF_ID141 | LKLDGKF | Alpha-2-HS-glycoprotein | Plasma | NA | MALDI-TOF | Normal | NA | 17269714 |
CancerPDF_ID148 | LILRDTKTYM | Alpha1-acid glycoprotein 1 | Plasma | NA | MALDI-TOF | Normal | NA | 17269714 |
CancerPDF_ID149 | SQRFPKAEF | Albumin | Plasma | NA | MALDI-TOF | Normal | NA | 17269714 |
CancerPDF_ID150 | GEYKFQNAL | Albumin | Plasma | NA | MALDI-TOF | Normal | NA | 17269714 |
CancerPDF_ID151 | GEYKFQNALL | Albumin | Plasma | NA | MALDI-TOF | Normal | NA | 17269714 |
CancerPDF_ID152 | TYVPKEFNAET | Albumin | Plasma | NA | MALDI-TOF | Normal | NA | 17269714 |
CancerPDF_ID155 | AEIHQSFQHL | "Alpha-1-antichymotrypsin, chain A" | Plasma | NA | MALDI-TOF | Normal | NA | 17269714 |
CancerPDF_ID156 | MSKVTNPKQA | "Alpha-1-antichymotrypsin, chain B" | Plasma | NA | MALDI-TOF | Normal | NA | 17269714 |
CancerPDF_ID161 | RPPGFSPF | Bradykinin | Serum | 904.4726 | MALDI-TOF | "Non-small cell lung cancer (NSCLC) patients, who were treated with first-line chemotherapy" | Peptide Ion Signature for differentiation between Short PFS(Progression Free survival) versus long PFS | 19728888 |
CancerPDF_ID268 | FYESDVMGR | Alpha-2-macroglobulin | Plasma | 552.2415 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID269 | HGPEGLRV | Alpha-2-macroglobulin | Plasma | 432.7345 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID272 | SFLSALEEYT | Apolipoprotein A-I | Plasma | 580.276 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID273 | FLSALEEYTK | Apolipoprotein A-I | Plasma | 600.8075 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID279 | LLPVLESFK | Apolipoprotein A-I | Plasma | 523.315 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID282 | HLAPYSDELR | Apolipoprotein A-I | Plasma | 600.8005 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID307 | DLDPEVRPT | Apolipoprotein C-III | Plasma | 521.261 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID312 | WVTDGFSSLK | Apolipoprotein C-III | Plasma | 570.287 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID328 | TVGSLAGQPL | Apolipoprotein E | Plasma | 471.763 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID331 | LGPLVEQGR | Apolipoprotein E | Plasma | 484.7765 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID337 | SPAINVAVHV | Transthyretin | Plasma | 503.7845 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID338 | AINVAVHV | Transthyretin | Plasma | 411.742 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID342 | VEGIYKVEI | Transthyretin | Plasma | 525.294 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID344 | FKDLGEENFK | Serum albumin | Plasma | 613.803 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID345 | DLGEENFK | Serum albumin | Plasma | 476.221 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID361 | LAPLAEDVR | Apolipoprotein A-IV | Plasma | 492.28 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID362 | TLSLPELEQQ | Apolipoprotein A-IV | Plasma | 579.3 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID363 | TLSLPELEQ | Apolipoprotein A-IV | Plasma | 515.27 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID369 | ISASAEELR | Apolipoprotein A-IV | Plasma | 488.26 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID374 | KIDQTVEELR | Apolipoprotein A-IV | Plasma | 615.83 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID375 | IDQTVEELR | Apolipoprotein A-IV | Plasma | 551.79 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID377 | RVEPYGENFN | Apolipoprotein A-IV | Plasma | 611.78 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID380 | GDVEGHLSF | Apolipoprotein A-IV | Plasma | 480.72 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID385 | LLPHANEVSQ | Apolipoprotein A-IV | Plasma | 554.29 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID387 | SELTQQLNALF | Apolipoprotein A-IV | Plasma | 632.33 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID398 | FLTQVKESL | Apolipoprotein C-II | Plasma | 532.8 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID436 | FDTASTGKTF | Fibrinogen alpha chain | Plasma | 537.76 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID457 | TGKTFPGFFS | Fibrinogen alpha chain | Plasma | 544.77 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID458 | TGKTFPGFF | Fibrinogen alpha chain | Plasma | 501.255 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID459 | TGKTFPGF | Fibrinogen alpha chain | Plasma | 427.72 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID461 | GKTFPGFFSP | Fibrinogen alpha chain | Plasma | 542.77 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID462 | GKTFPGFFS | Fibrinogen alpha chain | Plasma | 494.25 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID463 | GKTFPGFF | Fibrinogen alpha chain | Plasma | 450.73 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID464 | KTFPGFFSP | Fibrinogen alpha chain | Plasma | 514.26 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID465 | KTFPGFFS | Fibrinogen alpha chain | Plasma | 465.74 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID469 | GFFSPMLGEF | Fibrinogen alpha chain | Plasma | 566.26 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID470 | FFSPMLGEFV | Fibrinogen alpha chain | Plasma | 587.28 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID626 | GIAEFPSRG | Fibrinogen alpha chain | Plasma | 467.24 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID627 | GIAEFPSR | Fibrinogen alpha chain | Plasma | 438.73 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID630 | TNIMEILR | Fibrinogen alpha chain | Plasma | 495.27 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID645 | DFLAEGGGVR | Fibrinogen alpha chain | Plasma | 510.76 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID655 | DLGTLSGIGT | Fibrinogen alpha chain | Plasma | 467.24 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID664 | SGIGTLDGFR | Fibrinogen alpha chain | Plasma | 341.18 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID665 | GIGTLDGFR | Fibrinogen alpha chain | Plasma | 468.25 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID666 | IGTLDGFR | Fibrinogen alpha chain | Plasma | 439.74 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID670 | HRHPDEAAFF | Fibrinogen alpha chain | Plasma | 613.79 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID679 | ALTDMPQMRM | Fibrinogen alpha chain | Plasma | 597.27 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID680 | ALTDMPQM | Fibrinogen alpha chain | Plasma | 453.7 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID681 | LTDMPQMRM | Fibrinogen alpha chain | Plasma | 561.75 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID682 | LTDMPQMR | Fibrinogen alpha chain | Plasma | 496.23 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID719 | TYFPHFDLS | Hemoglobin subunit alpha | Plasma | 563.76 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID721 | SLDKFLASV | Hemoglobin subunit alpha | Plasma | 490.27 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID723 | DALTNAVAHV | Hemoglobin subunit alpha | Plasma | 505.76 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID730 | SAVTALWGK | Hemoglobin subunit beta | Plasma | 466.76 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID732 | TALWGKVNV | Hemoglobin subunit beta | Plasma | 494.28 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID739 | RPPGFSPFR | Kininogen-1 | Plasma | 530.78 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID740 | RPPGFSPF | Kininogen-1 | Plasma | 452.74 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID754 | AISAALKPAL | Apolipoprotein F | Plasma | 477.79 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID759 | REWFSETFQK | Apolipoprotein C-I | Plasma | 679.32 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID760 | REWFSETFQ | Apolipoprotein C-I | Plasma | 615.28 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID765 | DVSSALDKL | Apolipoprotein C-I | Plasma | 474.25 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID792 | GLPGPPDVPD | Inter-alpha-trypsin inhibitor heavy chain H4 | Plasma | 482.23 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID795 | PGPPDVPDHA | Inter-alpha-trypsin inhibitor heavy chain H4 | Plasma | 501.23 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID800 | PDHAAYHPF | Inter-alpha-trypsin inhibitor heavy chain H4 | Plasma | 527.73 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID801 | PGVLSSRQL | Inter-alpha-trypsin inhibitor heavy chain H4 | Plasma | 478.77 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID808 | SEMVVAGKLQ | Inter-alpha-trypsin inhibitor heavy chain H4 | Plasma | 531.28 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID809 | EMVVAGKLQD | Inter-alpha-trypsin inhibitor heavy chain H4 | Plasma | 545.28 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID810 | EMVVAGKLQ | Inter-alpha-trypsin inhibitor heavy chain H4 | Plasma | 487.76 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID812 | MNFRPGVLS | Inter-alpha-trypsin inhibitor heavy chain H4 | Plasma | 510.76 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID813 | MNFRPGVL | Inter-alpha-trypsin inhibitor heavy chain H4 | Plasma | 467.24 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID814 | NFRPGVLSSR | Inter-alpha-trypsin inhibitor heavy chain H4 | Plasma | 566.81 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID815 | NFRPGVLS | Inter-alpha-trypsin inhibitor heavy chain H4 | Plasma | 445.24 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID816 | FRPGVLSSR | Inter-alpha-trypsin inhibitor heavy chain H4 | Plasma | 509.79 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID817 | GVLSSRQL | Inter-alpha-trypsin inhibitor heavy chain H4 | Plasma | 430.25 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID836 | VNEPSILEMS | Apolipoprotein L1 | Plasma | 559.77 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID864 | DNEEGFFSAR | Fibrinogen beta chain | Plasma | 586.25 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID865 | GPPVSELITK | Histone H1.4 | Plasma | 520.79 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID894 | EELQFSLGSK | Complement C4-B | Plasma | 569.28 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID895 | ELQFSLGSK | Complement C4-B | Plasma | 504.76 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID909 | SEPQEVLHIG | PDZ and LIM domain protein 1 | Plasma | 554.78 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID922 | SASLPIQPH | hypothetical LOC727950 | Plasma | 475.25 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID928 | ITHRIHWESA | Complement C3 | Plasma | 625.32 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID932 | THRIHWESA | Complement C3 | Plasma | 568.78 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID935 | HRIHWESASL | Complement C3 | Plasma | 618.31 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID937 | RIHWESASL | Complement C3 | Plasma | 549.78 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID938 | IHWESASLLR | Complement C3 | Plasma | 606.32 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID939 | IHWESASLL | Complement C3 | Plasma | 528.27 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID940 | IHWESASL | Complement C3 | Plasma | 471.73 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID941 | HWESASLLR | Complement C3 | Plasma | 549.78 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID948 | TLDPERLGR | Complement C3 | Plasma | 528.79 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID949 | TLDPERLG | Complement C3 | Plasma | 450.73 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID952 | LDVSLQLPSR | Complement C3 | Plasma | 564.32 | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
CancerPDF_ID1019 | LAEGGGVR | Fibrinopeptide A | Serum | 758.45 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Downregulated in cancer vs normal with Ratio of median intensity (patients/Controls) = 0.66, 0.95 and 0.65 in prostate, bladder and breast cancer respectively" | 16395409 |
CancerPDF_ID1020 | FLAEGGGVR | Fibrinopeptide A | Serum | 905.5 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "For bladder (Lower) and for breast (Higher) Differential ion intensity in cancer compare to normal with Ratio of median intensity (patients/Controls) = 0.97, 0.73 and 1.48 in prostate, bladder and breast cancer respectively" | 16395409 |
CancerPDF_ID1021 | DFLAEGGGVR | Fibrinopeptide A | Serum | 1020.47 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Downregulated in cancer vs normal with Ratio of median intensity (patients/Controls) = 0.28, 0.28 and 0.47 in prostate, bladder and breast cancer respectively" | 16395409 |
CancerPDF_ID1039 | HWESASLL | Complement C3f | Serum | 942.44 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "For Breast (Lower) and for Bladder (Higher) Differential ion intensity in cancer compare to normal with Ratio of median intensity (patients/Controls) = 1.74, 5.18 and 0.58 in prostate, bladder and breast cancer respectively" | 16395409 |
CancerPDF_ID1040 | IHWESASLL | Complement C3f | Serum | 1055.6 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) = 227, 1051 and 1 in prostate, bladder and breast cancer respectively" | 16395409 |
CancerPDF_ID1041 | RIHWESASLL | Complement C3f | Serum | 1211.7 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =7.86, 10.8 and 0.01 in prostate, bladder and breast cancer respectively" | 16395409 |
CancerPDF_ID1059 | HAAYHPF | Inter-alpha-trypsin inhibitor heavy chain H4 | Serum | 842.4 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in Prostate cancer vs normal,Downregulated in Bladder cancer vs normal with Ratio of median intensity (patients/Controls) =1.49, 0.01 and 1.04 in prostate, bladder and breast cancer respectively" | 16395409 |
CancerPDF_ID1069 | HAAYHPFR | Inter-alpha-trypsin inhibitor heavy chain H14 | Serum | 998.45 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =121, 256 and 147 in prostate, bladder and breast cancer respectively" | 16395409 |
CancerPDF_ID1086 | HFFFPK | Clusterin precursor | Serum | 822.41 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =1.15, 4.66 and 0.76 in prostate, bladder and breast cancer respectively" | 16395409 |
CancerPDF_ID1087 | HFFFPKSRIV | Clusterin precursor | Serum | 1277.71 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =251, 1406 and 1 in prostate, bladder and breast cancer respectively" | 16395409 |
CancerPDF_ID1088 | RPPGFSPF | Bradykinin (and des-Arg bradykinin) | Serum | 904.48 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "For bladder (Lower) and for breast (Higher) Differential ion intensity in cancer compare to normal with Ratio of median intensity (patients/Controls) =1.06, 0.79 and 1.62 in prostate, bladder and breast cancer respectively" | 16395409 |
CancerPDF_ID1089 | RPPGFSPFR | Bradykinin (and des-Arg bradykinin) | Serum | 1060.57 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "For bladder (Lower) and for breast (Higher) Differential ion intensity in cancer compare to normal with Ratio of median intensity (patients/Controls) =0.77, 0.43 and 1.9 in prostate, bladder and breast cancer respectively" | 16395409 |
CancerPDF_ID1206 | LAEGGGVR | Fibrinogen alpha | Serum | 757.40825 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1207 | DFLAEGGGV | Fibrinogen alpha | Serum | 863.4025 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1208 | FLAEGGGVR | Fibrinogen alpha | Serum | 904.47667 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1209 | DFLAEGGGVR | Fibrinogen alpha | Serum | 1019.50361 | LC-MS | Colorectal cancer | Differentially expressed between cancer vs normal | 21136997 |
CancerPDF_ID1211 | DSTFESKSY | Fibrinogen alpha | Serum | 1062.45057 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1214 | GDSTFESKSY | Fibrinogen alpha | Serum | 1119.47203 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1310 | SSSYSKQFTS | Fibrinogen alpha | Serum | 1120.50367 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1339 | KQFTSSTSYN | Fibrinogen alpha | Serum | 1161.53022 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1352 | GHAKSRPV | Fibrinogen alpha | Serum | 850.47733 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1353 | DFLAEGGG | Fibrinogen alpha | Serum | 764.33408 | LC-MS | Colorectal cancer | Differentially expressed between cancer vs normal | 21136997 |
CancerPDF_ID1354 | LAEDVRGN | Apolipoprotein A-IV | Serum | 872.43519 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1355 | ASAEELRQ | Apolipoprotein A-IV | Serum | 902.44576 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1356 | ISASAEELR | Apolipoprotein A-IV | Serum | 974.50327 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1357 | LAPLAEDVR | Apolipoprotein A-IV | Serum | 982.54475 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1358 | LAEDVRGNL | Apolipoprotein A-IV | Serum | 985.51926 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1359 | SASAEELRQ | Apolipoprotein A-IV | Serum | 989.47779 | LC-MS | Colorectal cancer | Differentially expressed between cancer vs normal | 21136997 |
CancerPDF_ID1360 | APLAEDVRGN | Apolipoprotein A-IV | Serum | 1040.52507 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1361 | IDQNVEELK | Apolipoprotein A-IV | Serum | 1086.5557 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1362 | ISASAEELRQ | Apolipoprotein A-IV | Serum | 1102.56185 | LC-MS | Colorectal cancer | Differentially expressed between cancer vs normal | 21136997 |
CancerPDF_ID1364 | QVNTQAEQLR | Apolipoprotein A-IV | Serum | 1185.6102 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1365 | KIDQTVEELR | Apolipoprotein A-IV | Serum | 1229.66157 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1370 | AEDVRGNLR | Apolipoprotein A-IV | Serum | 1028.53631 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1371 | VKIDQTVEEL | Apolipoprotein A-IV | Serum | 1172.62887 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1372 | KIDQNVEELK | Apolipoprotein A-IV | Serum | 1214.65067 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1396 | GNTEGLQK | Apolipoprotein A-IV | Serum | 845.4243 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1398 | LAEDVRGNLR | Apolipoprotein A-IV | Serum | 1141.62037 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1399 | LDQQVEEFR | Apolipoprotein A-IV | Serum | 1162.56185 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1401 | SASAEELR | Apolipoprotein A-IV | Serum | 861.41921 | LC-MS | Colorectal cancer | Differentially expressed between cancer vs normal | 21136997 |
CancerPDF_ID1402 | APLAEDVR | Apolipoprotein A-IV | Serum | 869.46068 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1403 | TPYADEFK | Apolipoprotein A-IV | Serum | 969.44436 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1404 | DQNVEELK | Apolipoprotein A-IV | Serum | 973.47164 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1405 | TQVNTQAEQL | Apolipoprotein A-IV | Serum | 1130.55677 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1406 | AKIDQNVEEL | Apolipoprotein A-IV | Serum | 1157.59282 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1413 | TQVNTQAEQ | Apolipoprotein A-IV | Serum | 1017.4727 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1414 | DQNVEELKG | Apolipoprotein A-IV | Serum | 1030.4931 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1415 | RVEPYGENFN | Apolipoprotein A-IV | Serum | 1223.5571 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1416 | RLTPYADEFK | Apolipoprotein A-IV | Serum | 1238.62954 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1425 | IDQTVEELR | Apolipoprotein A-IV | Serum | 1101.5666 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1426 | QLTPYAQRME | Apolipoprotein A-IV | Serum | 1235.59686 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1428 | DQTVEELR | Apolipoprotein A-IV | Serum | 988.48254 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1429 | TPYAQRME | Apolipoprotein A-IV | Serum | 994.45422 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1430 | IDQNVEELKG | Apolipoprotein A-IV | Serum | 1143.57717 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1433 | KIDQTVEEL | Apolipoprotein A-IV | Serum | 1073.56045 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1434 | PLAEDVRGNL | Apolipoprotein A-IV | Serum | 1082.57202 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1435 | GRLTPYADEF | Apolipoprotein A-IV | Serum | 1167.55604 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1436 | DQNVEELKGR | Apolipoprotein A-IV | Serum | 1186.59421 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1437 | LVQQMEQLRQ | Apolipoprotein A-IV | Serum | 1271.66561 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1446 | VNTQAEQLR | Apolipoprotein A-IV | Serum | 1057.55162 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1451 | KIDQNVEEL | Apolipoprotein A-IV | Serum | 1086.5557 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1454 | ASAEELR | Apolipoprotein A-IV | Serum | 774.38718 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1455 | IGDNLRELQ | Apolipoprotein A-IV | Serum | 1056.55637 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1457 | ASHLGLAR | Complement C3 | Serum | 823.46644 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1458 | SVQLTEKR | Complement C3 | Serum | 959.53999 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1459 | WESASLLR | Complement C3 | Serum | 960.50288 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1460 | IHWESASLL | Complement C3 | Serum | 1054.54475 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1461 | SVQLTEKRM | Complement C3 | Serum | 1090.58048 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1463 | TLDPERLGR | Complement C3 | Serum | 1055.57236 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1464 | GYTQQLAFR | Complement C3 | Serum | 1082.55089 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1475 | QGALELIK | Complement C3 | Serum | 870.51747 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1476 | TGLQEVEVK | Complement C3 | Serum | 1001.53933 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1477 | VLLDGVQNPR | Complement C3 | Serum | 1109.61931 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1478 | RQGALELIKK | Complement C3 | Serum | 1154.71354 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1483 | SVQLTEKRMD | Complement C3 | Serum | 1205.60742 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1497 | FGLEKR | Complement C3 | Serum | 748.42317 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1498 | LLDGVQNPR | Complement C3 | Serum | 1010.55089 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1499 | RQGALELIK | Complement C3 | Serum | 1026.61858 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1500 | ELSEAEQATR | Complement C3 | Serum | 1132.53603 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1502 | YHHFISDGVR | Complement C3 | Serum | 1229.59415 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1511 | QGALELIKK | Complement C3 | Serum | 998.61243 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1512 | SVQLTEKRMD | Complement C3 | Serum | 1221.60234 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1527 | IHWESASL | Complement C3 | Serum | 941.46068 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1528 | SLKVVPEGIR | Complement C3 | Serum | 1096.66044 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1531 | YTQQLAFR | Complement C3 | Serum | 1025.52943 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1547 | SVQLTEK | Complement C3 | Serum | 803.43888 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1555 | HWESASLL | Complement C3 | Serum | 941.46068 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1557 | DEPPQSPWDR | Apolipoprotein A-I | Serum | 1225.53637 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1561 | AHVDALR | Apolipoprotein A-I | Serum | 780.42424 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1562 | AKPALEDLR | Apolipoprotein A-I | Serum | 1011.57129 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1567 | KPALEDLR | Apolipoprotein A-I | Serum | 940.53418 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1568 | AELQEGARQ | Apolipoprotein A-I | Serum | 1000.49377 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1569 | THLAPYSDEL | Apolipoprotein A-I | Serum | 1144.54005 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1583 | EPPQSPWDR | Apolipoprotein A-I | Serum | 1110.50942 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1584 | WQEEMELYR | Apolipoprotein A-I | Serum | 1282.56522 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1590 | QGLLPVLESF | Apolipoprotein A-I | Serum | 1101.60701 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1605 | HLAPYSDELR | Apolipoprotein A-I | Serum | 1199.59349 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1606 | YSDELRQ | Apolipoprotein A-I | Serum | 909.41921 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1607 | TEHLSTLSEK | Apolipoprotein A-I | Serum | 1143.57717 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1609 | AELQEGARQK | Apolipoprotein A-I | Serum | 1128.58874 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1610 | PQGDAAQK | Alpha-1 protease inhibitor | Serum | 813.39808 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1611 | SASLHLPK | Alpha-1 protease inhibitor | Serum | 851.4865 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1612 | INDYVEK | Alpha-1 protease inhibitor | Serum | 879.4338 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1613 | EDPQGDAAQK | Alpha-1 protease inhibitor | Serum | 1057.46762 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1621 | SVLGQLGITK | Alpha-1 protease inhibitor | Serum | 1014.60735 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1624 | SPLFMGK | Alpha-1 protease inhibitor | Serum | 778.40475 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1625 | FLENEDR | Alpha-1 protease inhibitor | Serum | 921.41921 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1626 | SITGTYDLK | Alpha-1 protease inhibitor | Serum | 996.51278 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1627 | LSITGTYDLK | Alpha-1 protease inhibitor | Serum | 1109.59684 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1628 | KQINDYVEK | Alpha-1 protease inhibitor | Serum | 1135.58734 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1637 | FMGKVVNPTQ | Alpha-1 protease inhibitor | Serum | 1119.57467 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1640 | SPLFMGKVV | Alpha-1 protease inhibitor | Serum | 976.54157 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1642 | INDYVEKGTQ | Alpha-1 protease inhibitor | Serum | 1165.56152 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1649 | EDPQGDAAQ | Alpha-1 protease inhibitor | Serum | 929.37265 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1650 | FMGKVVNPT | Alpha-1 protease inhibitor | Serum | 991.51609 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1651 | NDYVEKGTQ | Alpha-1 protease inhibitor | Serum | 1052.47745 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1655 | NDYVEKGTQG | Alpha-1 protease inhibitor | Serum | 1109.49892 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1659 | PSGEVSHPR | Alpha-2-HS-glycoprotein | Serum | 964.47264 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1660 | SPSGEVSHPR | Alpha-2-HS-glycoprotein | Serum | 1051.50467 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1687 | GPLVEQGRVR | Apolipoprotein E | Serum | 1109.63054 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1696 | LGPLVEQGRV | Apolipoprotein E | Serum | 1066.61349 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1701 | LGPLVEQGR | Apolipoprotein E | Serum | 967.54508 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1712 | KDISEVVTPR | Complement factor B | Serum | 1142.62954 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1713 | ALFVSEEEKK | Complement factor B | Serum | 1178.6183 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1718 | DISEVVTPR | Complement factor B | Serum | 1014.53457 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1719 | DNEQHVFK | Complement factor B | Serum | 1015.47231 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1720 | QLNEINYEDH | Complement factor B | Serum | 1273.55749 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1725 | ALFVSEEEK | Complement factor B | Serum | 1050.52334 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1732 | ASDLTWDNLK | Serotransferrin | Serum | 1161.5666 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1743 | SDLTWDNLKG | Serotransferrin | Serum | 1147.55095 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1744 | SDLTWDNLK | Serotransferrin | Serum | 1090.52949 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1745 | SASDLTWDNL | Serotransferrin | Serum | 1120.50367 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1767 | ALYAQARA | Inter-alpha-trypsin inhibitor heavy chain H2 | Serum | 862.4661 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1768 | ALYAQARAK | Inter-alpha-trypsin inhibitor heavy chain H2 | Serum | 990.56106 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1769 | YAQARAKGK | Inter-alpha-trypsin inhibitor heavy chain H2 | Serum | 991.55631 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1770 | AKGKTAGLVR | Inter-alpha-trypsin inhibitor heavy chain H2 | Serum | 999.61891 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1771 | SIKEKTVGR | Inter-alpha-trypsin inhibitor heavy chain H2 | Serum | 1016.59784 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1772 | SSIKEKTVGR | Inter-alpha-trypsin inhibitor heavy chain H2 | Serum | 1103.62987 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1781 | NDLISATK | Inter-alpha-trypsin inhibitor heavy chain H2 | Serum | 860.46035 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1794 | AKGKTAGLV | Inter-alpha-trypsin inhibitor heavy chain H2 | Serum | 843.5178 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1795 | SIKEKTVG | Inter-alpha-trypsin inhibitor heavy chain H2 | Serum | 860.49673 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1796 | SSIKEKTVG | Inter-alpha-trypsin inhibitor heavy chain H2 | Serum | 947.52876 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1814 | IADNKQSSF | Inter-alpha-trypsin inhibitor heavy chain H1 | Serum | 1008.48762 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1815 | ISGENAGLVR | Inter-alpha-trypsin inhibitor heavy chain H1 | Serum | 1014.54581 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1816 | AISGENAGLVR | Inter-alpha-trypsin inhibitor heavy chain H1 | Serum | 1085.58292 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1817 | KAAISGENAGLV | Inter-alpha-trypsin inhibitor heavy chain H1 | Serum | 1128.61389 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1818 | IADNKQSSFK | Inter-alpha-trypsin inhibitor heavy chain H1 | Serum | 1136.58259 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1819 | AAISGENAGLVR | Inter-alpha-trypsin inhibitor heavy chain H1 | Serum | 1156.62004 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1824 | SGENAGLVR | Inter-alpha-trypsin inhibitor heavy chain H1 | Serum | 901.46174 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1825 | AAISGENAGLV | Inter-alpha-trypsin inhibitor heavy chain H1 | Serum | 1000.51892 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1828 | KAAISGENAGL | Inter-alpha-trypsin inhibitor heavy chain H1 | Serum | 1029.54547 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1833 | EYQTFFNPR | Prothrombin | Serum | 1200.55637 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1834 | SEYQTFFNPR | Prothrombin | Serum | 1287.5884 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1844 | ENLDRDIALM | Prothrombin | Serum | 1188.58087 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1846 | GRVTGWGNLK | Prothrombin | Serum | 1086.59343 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1853 | GSEMVVAGK | Inter-alpha-trypsin inhibitor heavy chain H4 | Serum | 876.4375 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1854 | GPPDVPDHA | Inter-alpha-trypsin inhibitor heavy chain H4 | Serum | 903.40865 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1859 | GNDHSATRER | Inter-alpha-trypsin inhibitor heavy chain H4 | Serum | 1141.52245 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1864 | EMVVAGKLQ | Inter-alpha-trypsin inhibitor heavy chain H4 | Serum | 973.52665 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1887 | PPGFSPFR | Kininogen-1 | Serum | 903.46029 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1888 | ITEATKTVG | Kininogen-1 | Serum | 918.50221 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1889 | RPPGFSPFR | Kininogen-1 | Serum | 1059.5614 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1890 | RPPGFSPFR | Kininogen-1 | Serum | 1059.5614 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1891 | QRQVVAGLNF | Kininogen-1 | Serum | 1130.61964 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1894 | RHDWGHEKQR | Kininogen-1 | Serum | 1347.65446 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1897 | RPPGFSPF | Kininogen-1 | Serum | 903.46029 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1898 | SHALQLNNR | Complement C4-B | Serum | 1051.55229 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1899 | SRDKGQAGLQ | Complement C4-B | Serum | 1058.54687 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1916 | SHALQLNN | Complement C4-B | Serum | 895.45118 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1923 | QGSFQGGFR | Complement C4-A | Serum | 982.46208 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1945 | FYESDVMGR | Alpha-2-macroglobulin | Serum | 1102.47534 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1947 | SLNEEAVKK | Alpha-2-macroglobulin | Serum | 1016.55022 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1956 | YESDVMGR | Alpha-2-macroglobulin | Serum | 955.40693 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1958 | YESDVMGRG | Alpha-2-macroglobulin | Serum | 1012.42839 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1960 | YESDVMGRGH | Alpha-2-macroglobulin | Serum | 1149.48731 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1970 | ADLSGITGAR | Alpha-1-antichymotrypsin | Serum | 959.50361 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1971 | NLAVSQVVHK | Alpha-1-antichymotrypsin | Serum | 1093.62439 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1976 | DFLQSLK | Alpha-2-antiplasmin | Serum | 849.45962 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1985 | VNEPSILEMS | Apolipoprotein-L1 | Serum | 1117.53253 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1992 | ILQADQEL | Apolipoprotein-L1 | Serum | 928.48656 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1996 | SPELQAEAK | Apolipoprotein A-II | Serum | 971.49238 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1998 | SKEQLTPLI | Apolipoprotein A-II | Serum | 1027.59136 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID1999 | VKSPELQAEA | Apolipoprotein A-II | Serum | 1070.56079 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2015 | TPALHFK | Apolipoprotein B-100 | Serum | 812.45447 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2016 | KSHDELPR | Apolipoprotein B-100 | Serum | 980.50394 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2017 | EKSHDELPR | Apolipoprotein B-100 | Serum | 1109.54654 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2018 | AEKSHDELPR | Apolipoprotein B-100 | Serum | 1180.58365 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2024 | DLKVEDIPLA | Apolipoprotein B-100 | Serum | 1111.61249 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2025 | RPHFFFPK | Clusterin | Serum | 1074.57632 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2028 | TLLSNLEEAK | Clusterin | Serum | 1116.60265 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2030 | TLIEKTNEER | Clusterin | Serum | 1231.64083 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2036 | VNDLYIQK | Heparin cofactor 2 | Serum | 991.53385 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2037 | TLEAQLTPR | Heparin cofactor 2 | Serum | 1027.56621 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2039 | SVNDLYIQK | Heparin cofactor 2 | Serum | 1078.56587 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2040 | RNFGYTLR | Heparin cofactor 2 | Serum | 1025.54066 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2067 | MAVEDIISR | Complement component C8 alpha | Serum | 1032.52738 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2068 | AMAVEDIISR | Complement component C8 alpha | Serum | 1103.56449 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2075 | AARLPVAPLR | Complement C1s subcomponent | Serum | 1062.6662 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2081 | NADYSYSVWK | Complement C5 | Serum | 1231.55095 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2083 | TLLPVSKPEI | Complement C5 | Serum | 1095.65396 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2090 | VGQDSPEPR | Plexin domain-containing protein 2 | Serum | 983.46722 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2096 | VGYVSGWGRN | Haptoglobin | Serum | 1093.53049 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2097 | VGYVSGWGR | Haptoglobin | Serum | 979.48756 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2099 | VAAGAFQGLR | Leucine-rich alpha-2-glycoprotein | Serum | 988.54541 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2101 | AGAFQGLR | Leucine-rich alpha-2-glycoprotein | Serum | 818.43989 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2103 | YLFLNGNKLA | Leucine-rich alpha-2-glycoprotein | Serum | 1151.63389 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2116 | NSVIKVPMMN | Plasma protease C1 inhibitor | Serum | 1131.57804 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2119 | NDNEEGFFS | Fibrinogen beta | Serum | 1057.39887 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2122 | DNEEGFFSA | Fibrinogen beta | Serum | 1014.39306 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2124 | DNEEGFF | Fibrinogen beta | Serum | 856.32391 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2125 | NDNEEGFF | Fibrinogen beta | Serum | 970.36684 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2126 | DNEEGFFS | Coagulation factor XII | Serum | 943.35594 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2127 | IPPWEAPKE | Coagulation factor XII | Serum | 1065.5495 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2130 | MRDVVLFEK | Plasminogen | Serum | 1135.60597 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2137 | DNEDFQESNR | Ceruloplasmin | Serum | 1252.49562 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2146 | RGEKELLVPR | Alpha-1B-glycoprotein | Serum | 1195.70371 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2147 | GVTFLLR | Alpha-1B-glycoprotein | Serum | 804.48577 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2167 | SNEKAEEWGR | Serum amyloid A-4 protein | Serum | 1204.54726 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2169 | PMRGESVTVT | Coagulation factor V | Serum | 1075.53319 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2170 | SEAYNTFSER | Coagulation factor V | Serum | 1202.52038 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2174 | NFPSPVDAAF | Hemopexin precursor (Beta-1B-glycoprotein) | Serum | 1063.49746 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2188 | SENINHNSAF | Complement component C6 | Serum | 1131.4945 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2193 | SSPVLDAVPR | Serine/arginine repetitive matrix protein 2 | Serum | 1039.56621 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2194 | TPDVSSALDK | Apolipoprotein C-I | Serum | 1031.5135 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2195 | VKEKLKIDS | Apolipoprotein C-I | Serum | 1058.63356 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2200 | CKDLQL | Collagen alpha-1(V) chain | Serum | 718.36836 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2201 | NNANGVDLNR | Carboxypeptidase N catalytic chain | Serum | 1085.52138 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2202 | TSTTIPT | Mucin-16 | Serum | 719.37013 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2205 | EGSDDEEEG | Splicing factor 3 subunit 1 | Serum | 965.30978 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2206 | NDLLSATK | Nucleoprotein TPR | Serum | 860.46035 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2208 | LAENGVR | Receptor-type tyrosine-protein phosphatase N2 | Serum | 757.40825 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2213 | VAAEDWK | Ig alpha-1 chain C region | Serum | 817.39702 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2215 | KDTSIMQ | Echinoderm microtubule-associated protein-like 1 | Serum | 821.3953 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2227 | WLTAVDVP | Forkhead box protein N4 | Serum | 899.47527 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2228 | KDNVEEIQ | Ciliary dynein heavy chain 9 | Serum | 973.47164 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2230 | AASEQHVFK | Pre-mRNA-splicing factor ATP-dependent RNA helicase PRP16 | Serum | 1015.50869 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2234 | ASQEAELQL | Ciliary dynein heavy chain 11 | Serum | 987.48729 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2239 | DFIKSLK | ATP-binding cassette sub-family A member 6 | Serum | 849.496 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2245 | MLMASPSMED | Cell division cycle and apoptosis regulator protein 1 | Serum | 1110.43955 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2249 | CQDLKL | Collagen alpha-2(XI) chain | Serum | 718.36836 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2259 | DGNDHSLWR | Complement C2 | Serum | 1098.48427 | LC-MS | Colorectal cancer | NA | 21136997 |
CancerPDF_ID2270 | QHLPLI | Fibrinogen alpha | Plasma | 719.433 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2271 | DLVPGNF | Fibrinogen alpha | Plasma | 760.3756 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2272 | ALAREVDL | Fibrinogen alpha | Plasma | 885.492 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2273 | ALTDMPQM | Fibrinogen alpha | Plasma | 905.3987 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2274 | VPDLVPGNF | Fibrinogen alpha | Plasma | 956.4967 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2275 | LTDMPQMR | Fibrinogen alpha | Plasma | 990.4627 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2276 | LQKVPPEW | Fibrinogen alpha | Plasma | 995.544 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2277 | MELERPGGN | Fibrinogen alpha | Plasma | 1001.46 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2278 | ALTDMPQMR | Fibrinogen alpha | Plasma | 1061.4998 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2279 | ALTDMPQMR | Fibrinogen alpha | Plasma | 1077.4947 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2280 | VPDLVPGNFK | Fibrinogen alpha | Plasma | 1084.5917 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2281 | LVTSKGDKEL | Fibrinogen alpha | Plasma | 1088.6077 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2282 | DRQHLPLIK | Fibrinogen alpha | Plasma | 1118.656 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2283 | GDSTFESKSY | Fibrinogen alpha | Plasma | 1119.472 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2284 | QLQKVPPEW | Fibrinogen alpha | Plasma | 1123.6026 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2286 | LKNSLFEYQ | Fibrinogen alpha | Plasma | 1140.5815 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2288 | QFTSSTSYNR | Fibrinogen alpha | Plasma | 1189.5364 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2289 | SQLQKVPPEW | Fibrinogen alpha | Plasma | 1210.6346 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2294 | QLQKVPPEWK | Fibrinogen alpha | Plasma | 1251.6976 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2435 | ALEDLR | Apolipoprotein A-I | Plasma | 715.3864 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2436 | KPALEDL | Apolipoprotein A-I | Plasma | 784.4331 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2437 | ARAHVDAL | Apolipoprotein A-I | Plasma | 851.4614 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2438 | AKPALEDL | Apolipoprotein A-I | Plasma | 855.4702 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2439 | LAARLEAL | Apolipoprotein A-I | Plasma | 855.5178 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2440 | YLDDFQK | Apolipoprotein A-I | Plasma | 927.4338 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2441 | KPALEDLR | Apolipoprotein A-I | Plasma | 940.5342 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2442 | AELQEGARQ | Apolipoprotein A-I | Plasma | 1000.4938 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2443 | LGEEMRDR | Apolipoprotein A-I | Plasma | 1004.4709 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2444 | ARAHVDALR | Apolipoprotein A-I | Plasma | 1007.5625 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2445 | AKPALEDLR | Apolipoprotein A-I | Plasma | 1011.5713 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2446 | HLAPYSDEL | Apolipoprotein A-I | Plasma | 1043.4924 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2447 | QGLLPVLESF | Apolipoprotein A-I | Plasma | 1101.607 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2448 | VQPYLDDFQ | Apolipoprotein A-I | Plasma | 1123.5186 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2449 | TEHLSTLSEK | Apolipoprotein A-I | Plasma | 1143.5772 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2450 | THLAPYSDEL | Apolipoprotein A-I | Plasma | 1144.54 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2452 | SPLGEEMRDR | Apolipoprotein A-I | Plasma | 1188.5557 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2453 | LAPYSDELRQ | Apolipoprotein A-I | Plasma | 1190.5932 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2455 | DEPPQSPWDR | Apolipoprotein A-I | Plasma | 1225.5364 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2460 | VQPYLDDFQK | Apolipoprotein A-I | Plasma | 1251.6136 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2462 | WQEEMELYR | Apolipoprotein A-I | Plasma | 1282.5652 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2475 | WQEEMELYRQ | Apolipoprotein A-I | Plasma | 1410.6238 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2550 | YADEFKV | Apolipoprotein A-IV | Plasma | 870.4123 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2551 | TPYADEFK | Apolipoprotein A-IV | Plasma | 969.4444 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2552 | ISASAEELR | Apolipoprotein A-IV | Plasma | 974.5033 | LC-MS | Normal | Differentially expressed between cancer vs normal | 21136997 |
CancerPDF_ID2553 | QLTPYAQR | Apolipoprotein A-IV | Plasma | 975.5138 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2554 | LAEDVRGNL | Apolipoprotein A-IV | Plasma | 985.5193 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2555 | SASAEELRQ | Apolipoprotein A-IV | Plasma | 989.4778 | LC-MS | Normal | Differentially expressed between cancer vs normal | 21136997 |
CancerPDF_ID2556 | FATELHER | Apolipoprotein A-IV | Plasma | 1001.493 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2557 | AEDVRGNLR | Apolipoprotein A-IV | Plasma | 1028.5363 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2558 | ALVQQMEQL | Apolipoprotein A-IV | Plasma | 1058.543 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2559 | QQMEQLRQ | Apolipoprotein A-IV | Plasma | 1059.5131 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2560 | KIDQTVEEL | Apolipoprotein A-IV | Plasma | 1073.5604 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2561 | KIDQNVEEL | Apolipoprotein A-IV | Plasma | 1086.5557 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2562 | IDQTVEELR | Apolipoprotein A-IV | Plasma | 1101.5666 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2563 | ISASAEELRQ | Apolipoprotein A-IV | Plasma | 1102.5618 | LC-MS | Normal | Differentially expressed between cancer vs normal | 21136997 |
CancerPDF_ID2564 | LLPHANEVSQ | Apolipoprotein A-IV | Plasma | 1106.572 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2565 | TQVNTQAEQL | Apolipoprotein A-IV | Plasma | 1130.5568 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2566 | IDQNVEELKG | Apolipoprotein A-IV | Plasma | 1143.5772 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2567 | SASAEELRQR | Apolipoprotein A-IV | Plasma | 1145.5789 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2568 | AKIDQNVEEL | Apolipoprotein A-IV | Plasma | 1157.5928 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2569 | VQQMEQLRQ | Apolipoprotein A-IV | Plasma | 1158.5815 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2570 | GRLTPYADEF | Apolipoprotein A-IV | Plasma | 1167.556 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2571 | VKIDQTVEEL | Apolipoprotein A-IV | Plasma | 1172.6289 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2572 | DKVNSFFSTF | Apolipoprotein A-IV | Plasma | 1190.5608 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2574 | RVEPYGENFN | Apolipoprotein A-IV | Plasma | 1223.5571 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2575 | KIDQTVEELR | Apolipoprotein A-IV | Plasma | 1229.6616 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2576 | IDQTVEELRR | Apolipoprotein A-IV | Plasma | 1257.6677 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2580 | LVQQMEQLRQ | Apolipoprotein A-IV | Plasma | 1271.6656 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2647 | LKGPLLN | Complement C3 | Plasma | 753.4749 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2648 | SSAFAAFV | Complement C3 | Plasma | 798.3912 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2649 | LDPERLG | Complement C3 | Plasma | 798.4236 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2650 | SSKITHR | Complement C3 | Plasma | 827.4614 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2651 | IFTVNHK | Complement C3 | Plasma | 857.4759 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2652 | QGALELIK | Complement C3 | Plasma | 870.5175 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2653 | NEQVEIR | Complement C3 | Plasma | 886.4508 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2654 | IWDVVEK | Complement C3 | Plasma | 887.4753 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2655 | HHFISDGV | Complement C3 | Plasma | 910.4297 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2656 | VGKYPKEL | Complement C3 | Plasma | 932.5331 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2657 | SLKVVPEGI | Complement C3 | Plasma | 940.5593 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2658 | QGALELIKK | Complement C3 | Plasma | 998.6124 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2659 | LLNKFLTTA | Complement C3 | Plasma | 1019.6015 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2660 | QPSSAFAAFV | Complement C3 | Plasma | 1023.5026 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2661 | IHWESASLL | Complement C3 | Plasma | 1054.5448 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2662 | TLDPERLGR | Complement C3 | Plasma | 1055.5724 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2663 | YHHFISDGV | Complement C3 | Plasma | 1073.493 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2664 | GYTQQLAFR | Complement C3 | Plasma | 1082.5509 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2665 | SLKVVPEGIR | Complement C3 | Plasma | 1096.6604 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2666 | HWESASLLR | Complement C3 | Plasma | 1097.5618 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2667 | KVLLDGVQNL | Complement C3 | Plasma | 1097.6445 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2668 | VQLTEKRMD | Complement C3 | Plasma | 1118.5754 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2669 | KAGDFLEANY | Complement C3 | Plasma | 1126.5295 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2670 | VYHHFISDGV | Complement C3 | Plasma | 1172.5615 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2672 | SVQLTEKRMD | Complement C3 | Plasma | 1205.6074 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2673 | IHWESASLLR | Complement C3 | Plasma | 1210.6459 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2740 | AKAAATQK | Fibrinogen beta chain | Plasma | 787.4552 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2741 | RPFFPQ | Fibrinogen beta chain | Plasma | 790.4126 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2742 | KWDPYK | Fibrinogen beta chain | Plasma | 835.4228 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2743 | DLWQKR | Fibrinogen beta chain | Plasma | 844.4555 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2744 | GSWYSMR | Fibrinogen beta chain | Plasma | 885.3803 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2745 | RPAKAAATQ | Fibrinogen beta chain | Plasma | 912.5141 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2746 | KREEAPSL | Fibrinogen beta chain | Plasma | 928.4978 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2747 | REEAPSLR | Fibrinogen beta chain | Plasma | 956.5039 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2748 | QDGSVDFGR | Fibrinogen beta chain | Plasma | 979.4359 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2750 | YQISVNKY | Fibrinogen beta chain | Plasma | 1013.5182 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2751 | IRPFFPQQ | Fibrinogen beta chain | Plasma | 1031.5552 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2752 | RPAKAAATQK | Fibrinogen beta chain | Plasma | 1040.6091 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2753 | QDGSVDFGRK | Fibrinogen beta chain | Plasma | 1107.5309 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2756 | YQISVNKYR | Fibrinogen beta chain | Plasma | 1169.6193 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2757 | EDGGGWWYNR | Fibrinogen beta chain | Plasma | 1238.5105 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2805 | ASLHLPK | Alpha-1 protease inhibitor | Plasma | 764.4545 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2806 | SPLFMGK | Alpha-1 protease inhibitor | Plasma | 778.4048 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2807 | VLTIDEK | Alpha-1 protease inhibitor | Plasma | 816.4593 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2808 | SASLHLPK | Alpha-1 protease inhibitor | Plasma | 851.4865 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2809 | SVLGQLGIT | Alpha-1 protease inhibitor | Plasma | 886.5124 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2810 | AVLTIDEK | Alpha-1 protease inhibitor | Plasma | 887.4964 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2811 | FLENEDR | Alpha-1 protease inhibitor | Plasma | 921.4192 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2812 | QINDYVEK | Alpha-1 protease inhibitor | Plasma | 1007.4924 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2813 | SVLGQLGITK | Alpha-1 protease inhibitor | Plasma | 1014.6074 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2814 | LVDKFLEDV | Alpha-1 protease inhibitor | Plasma | 1076.5754 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2815 | FLENEDRR | Alpha-1 protease inhibitor | Plasma | 1077.5203 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2816 | LSITGTYDLK | Alpha-1 protease inhibitor | Plasma | 1109.5968 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2817 | KQINDYVEK | Alpha-1 protease inhibitor | Plasma | 1135.5873 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2818 | LVDKFLEDVK | Alpha-1 protease inhibitor | Plasma | 1204.6703 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2855 | NWIQYK | Fibrinogen gamma | Plasma | 850.4337 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2856 | VGPEADKY | Fibrinogen gamma | Plasma | 877.4182 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2857 | LDGSVDFK | Fibrinogen gamma | Plasma | 879.4338 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2858 | TSEVKQLI | Fibrinogen gamma | Plasma | 916.523 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2859 | KNWIQYK | Fibrinogen gamma | Plasma | 978.5287 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2860 | ELEDWNGR | Fibrinogen gamma | Plasma | 1017.4516 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2861 | VGPEADKYR | Fibrinogen gamma | Plasma | 1033.5193 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2862 | RLDGSVDFK | Fibrinogen gamma | Plasma | 1035.5349 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2863 | TSEVKQLIK | Fibrinogen gamma | Plasma | 1044.6179 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2864 | TTMKIIPFN | Fibrinogen gamma | Plasma | 1063.5736 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2865 | VELEDWNGR | Fibrinogen gamma | Plasma | 1116.52 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2866 | TSTADYAMFK | Fibrinogen gamma | Plasma | 1133.5063 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2867 | FFTSHNGMQF | Fibrinogen gamma | Plasma | 1214.5179 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2899 | SIKEKTVG | Inter-alpha-trypsin inhibitor heavy chain H2 | Plasma | 860.4967 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2900 | ALYAQARA | Inter-alpha-trypsin inhibitor heavy chain H2 | Plasma | 862.4661 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2901 | MKQTVEAM | Inter-alpha-trypsin inhibitor heavy chain H2 | Plasma | 936.4409 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2902 | DKHADPDFT | Inter-alpha-trypsin inhibitor heavy chain H2 | Plasma | 1044.4512 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2903 | LSNENHGIAQ | Inter-alpha-trypsin inhibitor heavy chain H2 | Plasma | 1081.5152 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2904 | SSIKEKTVGR | Inter-alpha-trypsin inhibitor heavy chain H2 | Plasma | 1103.6299 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2905 | FYNQVSTPLL | Inter-alpha-trypsin inhibitor heavy chain H2 | Plasma | 1180.6128 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2927 | ISVIRPS | Complement factor B | Plasma | 770.465 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2928 | DNEQHVF | Complement factor B | Plasma | 887.3774 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2929 | GDSGGPLIVH | Complement factor B | Plasma | 950.4821 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2930 | VASYGVKPR | Complement factor B | Plasma | 975.5502 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2931 | LFVSEEEK | Complement factor B | Plasma | 979.4862 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2932 | DISEVVTPR | Complement factor B | Plasma | 1014.5346 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2933 | KDNEQHVF | Complement factor B | Plasma | 1015.4723 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2934 | ALFVSEEEK | Complement factor B | Plasma | 1050.5233 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2935 | KDISEVVTPR | Complement factor B | Plasma | 1142.6295 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2936 | ALFVSEEEKK | Complement factor B | Plasma | 1178.6183 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2938 | NEINYEDHKL | Complement factor B | Plasma | 1273.5939 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2953 | AQAWGERL | Apolipoprotein E | Plasma | 929.4719 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2954 | MEEMGSRT | Apolipoprotein E | Plasma | 939.379 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2955 | LGPLVEQGRV | Apolipoprotein E | Plasma | 1066.6135 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID2993 | DNEDFQESNR | Ceruloplasmin | Plasma | 1252.4956 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3014 | QAGAAGSR | Inter-alpha-trypsin inhibitor heavy chain H4 | Plasma | 716.3566 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3015 | VRPQQLV | Inter-alpha-trypsin inhibitor heavy chain H4 | Plasma | 838.5025 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3016 | NFRPGVLSS | Inter-alpha-trypsin inhibitor heavy chain H4 | Plasma | 975.5138 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3017 | IQQTREALI | Inter-alpha-trypsin inhibitor heavy chain H4 | Plasma | 1070.6084 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3018 | FKPTLSQQQ | Inter-alpha-trypsin inhibitor heavy chain H4 | Plasma | 1075.5662 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3019 | MNFRPGVLSS | Inter-alpha-trypsin inhibitor heavy chain H4 | Plasma | 1106.5543 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3020 | NFRPGVLSSR | Inter-alpha-trypsin inhibitor heavy chain H4 | Plasma | 1131.6149 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3039 | IADNKQSSF | Inter-alpha-trypsin inhibitor heavy chain H1 | Plasma | 1008.4876 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3040 | AISGENAGLVR | Inter-alpha-trypsin inhibitor heavy chain H1 | Plasma | 1085.5829 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3041 | KAAISGENAGLV | Inter-alpha-trypsin inhibitor heavy chain H1 | Plasma | 1128.6139 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3042 | AAISGENAGLVR | Inter-alpha-trypsin inhibitor heavy chain H1 | Plasma | 1156.62 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3051 | VWVYPPEK | Hemopexin | Plasma | 1016.5331 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3052 | NFPSPVDAAF | Hemopexin | Plasma | 1063.4975 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3054 | WDRELISER | Hemopexin | Plasma | 1202.6044 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3055 | DRELISERW | Hemopexin | Plasma | 1202.6044 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3059 | KWDRELISER | Hemopexin | Plasma | 1330.6994 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3061 | WDRELISERW | Hemopexin | Plasma | 1388.6837 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3073 | LDFKENAEQS | Antithrombin-III | Plasma | 1179.5408 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3086 | EVLLPKF | Heparin cofactor 2 | Plasma | 844.5058 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3087 | VNDLYIQK | Heparin cofactor 2 | Plasma | 991.5338 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3088 | REVLLPKF | Heparin cofactor 2 | Plasma | 1000.607 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3089 | RNFGYTLR | Heparin cofactor 2 | Plasma | 1025.5407 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3090 | KGPLDQLEK | Heparin cofactor 2 | Plasma | 1026.571 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3091 | TLEAQLTPR | Heparin cofactor 2 | Plasma | 1027.5662 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3092 | TNNHIMKLT | Heparin cofactor 2 | Plasma | 1070.5543 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3093 | SVNDLYIQK | Heparin cofactor 2 | Plasma | 1078.5659 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3094 | FPILLDFKT | Heparin cofactor 2 | Plasma | 1092.6219 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3095 | TREVLLPKF | Heparin cofactor 2 | Plasma | 1101.6546 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3096 | QFPILLDFK | Heparin cofactor 2 | Plasma | 1119.6328 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3098 | QFPILLDFKT | Heparin cofactor 2 | Plasma | 1220.6805 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3105 | DSLEFR | Alpha-1-antichymotrypsin | Plasma | 765.3657 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3106 | ADLSGITGAR | Alpha-1-antichymotrypsin | Plasma | 959.5036 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3107 | NLAVSQVVHK | Alpha-1-antichymotrypsin | Plasma | 1093.6244 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3115 | KGGVASGF | Gelsolin | Plasma | 721.3759 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3116 | DGKIFVW | Gelsolin | Plasma | 863.4541 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3117 | YIETDPANR | Gelsolin | Plasma | 1077.5091 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3118 | AGKEPGLQIW | Gelsolin | Plasma | 1097.5869 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3129 | DFLQSLK | Alpha-2-antiplasmin | Plasma | 849.4596 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3130 | RLPKLYL | Alpha-2-antiplasmin | Plasma | 901.5749 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3131 | GDKLFGPDLK | Alpha-2-antiplasmin | Plasma | 1088.5866 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3132 | RGDKLFGPDL | Alpha-2-antiplasmin | Plasma | 1116.5928 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3133 | NKFDPSLTQR | Alpha-2-antiplasmin | Plasma | 1204.62 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3157 | SHALQLNN | Complement C4-A | Plasma | 895.4512 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3158 | SHALQLNNR | Complement C4-A | Plasma | 1051.5523 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3173 | HFFFPK | Clusterin | Plasma | 821.4224 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3174 | HFFFPKS | Clusterin | Plasma | 908.4545 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3175 | FMETVAEK | Clusterin | Plasma | 953.4528 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3176 | RPHFFFPK | Clusterin | Plasma | 1074.5763 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3177 | TLLSNLEEAK | Clusterin | Plasma | 1116.6026 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3178 | RPHFFFPKS | Clusterin | Plasma | 1161.6084 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3179 | TLIEKTNEER | Clusterin | Plasma | 1231.6408 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3188 | DVSSALDK | Apolipoprotein C-I | Plasma | 833.4131 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3189 | TPDVSSALDK | Apolipoprotein C-I | Plasma | 1031.5135 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3190 | VKEKLKIDS | Apolipoprotein C-I | Plasma | 1058.6336 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3191 | REWFSETFQ | Apolipoprotein C-I | Plasma | 1228.5513 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3193 | MREWFSETFQ | Apolipoprotein C-I | Plasma | 1359.5918 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3208 | HTLNQIDEVK | Alpha-2-HS-glycoprotein | Plasma | 1195.6197 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3223 | EHQGGHV | Kininogen-1 | Plasma | 762.3409 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3224 | HGHGHGKH | Kininogen-1 | Plasma | 865.4056 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3225 | RPPGFSPF | Kininogen-1 | Plasma | 903.4603 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3226 | RPPGFSPFR | Kininogen-1 | Plasma | 1059.5614 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3228 | RHDWGHEKQR | Kininogen-1 | Plasma | 1347.6545 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3238 | ILQADQEL | Apolipoprotein-L1 | Plasma | 928.4866 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3239 | NWFLKEFPRL | Apolipoprotein-L1 | Plasma | 1348.7292 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3246 | QDTSFLN | Complement component C8 alpha chain | Plasma | 823.3712 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3247 | AVEDIISRV | Complement component C8 alpha chain | Plasma | 1000.5553 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3248 | AMAVEDIISR | Complement component C8 alpha chain | Plasma | 1103.5645 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3249 | MAVEDIISRV | Complement component C8 alpha chain | Plasma | 1131.5958 | LC-MS | Normal | NA | 21136997 |
CancerPDF_ID3254 | FLAEGGGVR | Fibrinopeptide A | Serum | 906 | MALDI-TOF | Stomach adenocarcinoma | NA | 21267442 |
CancerPDF_ID3409 | VLNLGPITR | Uromodulin | Urine | NA | CE-MS-TOF | Bladder cancer | Downregulated in cancer vs normal | 21591268 |
CancerPDF_ID3417 | DCGDNSDEEN | Low-density lipoprotein receptor-related protein 2 | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between primary UBC and normal individual | 27026199 |
CancerPDF_ID3418 | SAYQEAMDIS | "14-3-3 protein sigma, SFN" | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between primary UBC and normal individual | 27026199 |
CancerPDF_ID3424 | LSALEEYTKK | Apolipoprotein A-I | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between primary UBC and normal individual | 27026199 |
CancerPDF_ID3432 | EEYTKKLNTQ | Apolipoprotein A-I | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between primary UBC and normal individual | 27026199 |
CancerPDF_ID3522 | PpGEAGKpG | Collagen alpha-1(I) chain | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
CancerPDF_ID3524 | KLGHPDTL | Protein S100-A9 | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
CancerPDF_ID3528 | YQTNKAKH | Cystatin-B | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
CancerPDF_ID3531 | pGDRGEpGPp | Collagen alpha-1(I) chain | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
CancerPDF_ID3535 | RYVGGQEHF | Alpha-1-acid glycoprotein 1 | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
CancerPDF_ID3538 | SAYQEAMDIS | "14-3-3 protein sigma, SFN" | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
CancerPDF_ID3539 | RAHGQESAIF | Secreted and transmembrane protein 1 | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
CancerPDF_ID3545 | LSALEEYTKK | Apolipoprotein A-I | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
CancerPDF_ID3554 | EEYTKKLNTQ | Apolipoprotein A-I | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
CancerPDF_ID3574 | DEDEDEDNACLR | Pleckstrin homology domain-containing family G member 5 | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
CancerPDF_ID3576 | ERAEDEEEINAE | Myosin-3 | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
CancerPDF_ID3850 | FGYGYGPY | Statherin | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID3852 | GYGYGPY | Statherin | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID3855 | YQPVPEQPL | Statherin | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID3856 | YQQYTF | Statherin | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID3859 | QYQQYTF | Statherin | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID3862 | GGRPSRPPQ | Basic PRP1 (Basic salivary proline-rich protein 1) | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID3863 | GPPAQGGSK | Basic PRP1 (Basic salivary proline-rich protein 1) | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID3864 | GPPPPGKPQ | Basic PRP1 (Basic salivary proline-rich protein 1) | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID3865 | GPPPPGKPQ | Basic PRP1 (Basic salivary proline-rich protein 1) | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID3866 | GPPPPPGKPQ | Basic PRP1 (Basic salivary proline-rich protein 1) | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID3867 | GPPPPPGKPQ | Basic PRP1 (Basic salivary proline-rich protein 1) | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID3868 | GPPPPPGKPQ | Basic PRP1 (Basic salivary proline-rich protein 1) | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID3869 | GPPPQGDK | Basic PRP1 (Basic salivary proline-rich protein 1) | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID3875 | SPPGKPQ | Basic PRP1 (Basic salivary proline-rich protein 1) | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID3878 | GPPPQGDNK | Basic PRP1 (Basic salivary proline-rich protein 1) | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID3879 | GPPPQGGSK | Basic PRP2 (Basic salivary proline-rich protein 2) | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID3880 | GGRPSRPPQ | Basic PRP2 (Basic salivary proline-rich protein 2) | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID3881 | GPPPPGKPQ | Basic PRP2 (Basic salivary proline-rich protein 2) | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID3882 | GPPPPGKPQ | Basic PRP2 (Basic salivary proline-rich protein 2) | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID3885 | GPPPPPGKPQ | Basic PRP2 (Basic salivary proline-rich protein 2) | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID3886 | GPPPPPGKPQ | Basic PRP2 (Basic salivary proline-rich protein 2) | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID3887 | GPPPPPGKPQ | Basic PRP2 (Basic salivary proline-rich protein 2) | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID3888 | GPPPQGDK | Basic PRP2 (Basic salivary proline-rich protein 2) | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID3889 | GPPPQGDNK | Basic PRP2 (Basic salivary proline-rich protein 2) | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID3892 | GPPPQGGSK | Basic PRP2 (Basic salivary proline-rich protein 2) | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID3897 | SPPGKPQ | Basic PRP2 (Basic salivary proline-rich protein 2) | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID3900 | GPPPQGDNK | Basic PRP2 (Basic salivary proline-rich protein 2) | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID3901 | GPPPQGGSK | Basic PRP2 (Basic salivary proline-rich protein 2) | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID3902 | GGRPSRPPQ | Basic PRP2 (Basic salivary proline-rich protein 2) | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID3903 | GPPPPGKPQ | Basic PRP2 (Basic salivary proline-rich protein 2) | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID3904 | GPPPPGKPQ | Basic PRP2 (Basic salivary proline-rich protein 2) | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID3907 | GPPPPPGKPQ | Basic PRP2 (Basic salivary proline-rich protein 2) | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID3908 | GPPPPPGKPQ | Basic PRP2 (Basic salivary proline-rich protein 2) | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID3909 | GPPPPPGKPQ | Basic PRP2 (Basic salivary proline-rich protein 2) | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID3910 | GPPPPPGKPQ | Basic PRP2 (Basic salivary proline-rich protein 2) | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID3911 | GPPPQGDK | Basic PRP2 (Basic salivary proline-rich protein 2) | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID3912 | GPPPQGDNK | Basic PRP2 (Basic salivary proline-rich protein 2) | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID3915 | GPPPQGGSK | Basic PRP2 (Basic salivary proline-rich protein 2) | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID3920 | SPPGKPQ | Basic PRP2 (Basic salivary proline-rich protein 2) | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID3928 | GKPEGR | Basic PRP3 (Basic salivary proline-rich protein 3) | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID3929 | GPPPHPGKPQ | Basic PRP3 (Basic salivary proline-rich protein 3) | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID3937 | LISGKPEGR | Basic PRP4 (Basic salivary proline-rich protein 4) | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID3938 | RPQGGNQPQR | Basic PRP4 (Basic salivary proline-rich protein 4) | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID3939 | GKPEGR | Basic PRP4 (Basic salivary proline-rich protein 4) | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID3940 | GPPPHPGKPE | Basic PRP4 (Basic salivary proline-rich protein 4) | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID3941 | GPPPPGKPQ | Basic PRP4 (Basic salivary proline-rich protein 4) | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID3942 | SPPGKPQ | Basic PRP4 (Basic salivary proline-rich protein 4) | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID3946 | GIFPPPPPQP | Submaxillary gland androgen-regulated protein 3B | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID3949 | GPYPPGPL | Submaxillary gland androgen-regulated protein 3B | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID3971 | GPPPQGGRPQ | aPRP (phosphorylated acidic proline-rich proteins ) | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID3973 | GPPQGQSPQ | aPRP (phosphorylated acidic proline-rich proteins ) | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID3974 | GPPQQGGHP | aPRP (phosphorylated acidic proline-rich proteins ) | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID3979 | GPPQQGGHQQ | aPRP (phosphorylated acidic proline-rich proteins ) | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID3988 | DSEQFIDEER | aPRP (phosphorylated acidic proline-rich proteins ) | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID3989 | FIDEER | aPRP (phosphorylated acidic proline-rich proteins ) | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID3992 | GPPQGQSPQ | aPRP (phosphorylated acidic proline-rich proteins ) | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID3993 | GPPQGQSPQ | aPRP (phosphorylated acidic proline-rich proteins ) | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID3997 | GRPQGPPQQ | aPRP (phosphorylated acidic proline-rich proteins ) | Saliva | NA | LC-MS and iTRAQ | Normal | NA | 22809520 |
CancerPDF_ID4013 | DLENLH | Beta-casein | Human milk | NA | MALDI-TOF | Normal | Downregulated 3 fold in Pre-term case as compare to normal | 23891694 |
CancerPDF_ID4022 | DLENLHLPL | Beta-casein | Human milk | NA | MALDI-TOF | Normal | Downregulated 3 fold in Pre-term case as compare to normal | 23891694 |
CancerPDF_ID4041 | APVHNPISV | Beta-casein | Human milk | NA | MALDI-TOF | Normal | Downregulated 3 fold in Pre-term case as compare to normal | 23891694 |
CancerPDF_ID4138 | AEYGVYVKVT | Haptoglobin isoform 2 preproprotein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4161 | AFFTRAFDQI | "cDNA FLJ54957, highly similar to Transketolase" | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4195 | AGVVLSA | Isoform 2 of Multiple epidermal growth factor-like domains protein 6 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4214 | AIQDPRLFAE | Polymeric immunoglobulin receptor | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4234 | AKLYGRAPQL | Protein AMBP | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4236 | ALDFEQEMA | "Actin, cytoplasmic 1" | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4237 | ALDFEQEMAT | "Actin, cytoplasmic 1" | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4276 | ALTDMPQMRM | Isoform 1 of Fibrinogen alpha chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4318 | AQDFKTDLRF | Histone H3.1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4319 | AQDFKTDLRF | Histone H3.2 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4320 | AQDFKTDLRF | Histone H3.3 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4357 | ARGWVTDGF | Apolipoprotein C-III | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4364 | ASLAISA | Calpain-7 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4382 | ATLRETYGEM | Isoform 1 of Serum albumin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4391 | ATVVLGT | Isoform 2 of Perilipin-4 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4392 | AVADTRDQAD | Polymeric immunoglobulin receptor | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4413 | AVPWQGTMTL | Cystatin-C | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4419 | AVSDGVIKVF | Cofilin-1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4423 | AVYYCQQY | Ig kappa chain V-III region HAH | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4424 | AVYYCQQY | Ig kappa chain V-IV region Len | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4425 | AVYYCQQY | IGKat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4426 | AVYYCQQY | IGKat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4427 | AVYYCQQY | Myosin-reactive immunoglobulin light chain variable region | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4428 | AVYYCQQY | similar to hCG1686089 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4429 | AVYYCQQYY | Ig kappa chain V-IV region Len | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4458 | CIYQGRLWAF | Neutrophil defensin 1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4489 | CLKFPGGSC | HLA class II DR-beta | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4490 | CLLNNFYPRE | 26 kDa protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4491 | CLLNNFYPRE | 26 kDa protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4492 | CLLNNFYPRE | Ig kappa chain C region | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4493 | CLLNNFYPRE | Ig kappa chain C region | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4494 | CLLNNFYPRE | IGKat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4495 | CLLNNFYPRE | IGKat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4496 | CLLNNFYPRE | IGKat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4497 | CLLNNFYPRE | Putative uncharacterized protein IGKC | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4548 | DAPGQYGAYF | Basement membrane-specific heparan sulfate proteoglycan core protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4604 | DKFSEFWDLD | Apolipoprotein C-III | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4638 | DLPSLAADFV | Isoform 1 of Serum albumin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4643 | DLRVNFAMNV | Isoform M2 of Pyruvate kinase isozymes M1/M2 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4684 | DTTDGLGKVY | Isoform 1 of Nidogen-1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4703 | DWVQKTIAEN | Haptoglobin isoform 2 preproprotein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4774 | EQLGEYKFQNA | Isoform 1 of Serum albumin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4793 | FAQYLQQCPF | Isoform 1 of Serum albumin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4804 | FDMWGGDVA | Protein FAM3C | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4827 | FEQLGEYKF | Isoform 1 of Serum albumin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4828 | FEQLGEYKFQNA | Isoform 1 of Serum albumin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4830 | FFLPDEGKL | Isoform 1 of Alpha-1-antitrypsin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4831 | FFLPDEGKLQ | Isoform 1 of Alpha-1-antitrypsin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4833 | FFQGDREW | Hemopexin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4846 | FGGGTKLTV | hypothetical protein XP_002348153 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4847 | FGGGTKLTV | Ig lambda chain V-I region NEWM | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4848 | FGGGTKLTV | Ig lambda chain V-IV region Hil | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4849 | FGGGTKLTV | IGLat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4850 | FGGGTKLTV | IGLat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4851 | FGGGTKLTV | IGLat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4852 | FGGGTKLTV | IGLat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4853 | FGGGTKLTV | Immunglobulin light chain variable region (Fragment) | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4854 | FGGGTKLTV | Lambda-chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4855 | FGGGTKLTV | Putative uncharacterized protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4866 | FGSYLDDEKN | Alpha-1-acid glycoprotein 2 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4942 | FKLLPQLTY | Acidic leucine-rich nuclear phosphoprotein 32 family member A | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID4943 | FKLLPQLTY | Isoform 1 of Acidic leucine-rich nuclear phosphoprotein 32 family member B | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5004 | FQGDREWF | Hemopexin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5007 | FQGLRQLDM | Leucine-rich alpha-2-glycoprotein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5015 | FQYDTWKQS | Isoform 1 of Insulin-like growth factor II | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5020 | FRVGSEAEGY | Isoform 1 of Fibrinogen alpha chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5031 | FSKDWSFY | Beta-2-microglobulin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5040 | FSVDETGQM | Retinol-binding protein 4 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5041 | FSVMPGLKM | Isoform 2 of Inter-alpha-trypsin inhibitor heavy chain H4 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5046 | FSYSGAFKCL | "cDNA FLJ58679, highly similar to Lactotransferrin" | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5058 | FVELGTQPAT | Apolipoprotein A-II | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5066 | FVLKTPSAAY | Isoform 1 of Gelsolin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5068 | FVNDIFERI | Histone H2B type 1-C/E/F/G/I | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5069 | FVNDIFERI | Histone H2B type 1-K | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5070 | FVNDIFERI | Histone H2B type 1-L | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5078 | FVYLQEGKVI | Phosphatidylethanolamine-binding protein 4 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5087 | GADGVPGKD | Isoform 1 of Collagen alpha-1(III) chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5148 | GHPAPAP | similar to HSPC088 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5173 | GIPEDSIFTM | Protein AMBP | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5186 | GKSNFLNCYV | Beta-2-microglobulin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5196 | GLFEDTNLC | Histone H3.1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5197 | GLFEDTNLC | Histone H3.2 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5198 | GLFEDTNLC | Histone H3.3 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5225 | GLYLGSGYFT | "cDNA FLJ58679, highly similar to Lactotransferrin" | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5231 | GNDGARGSD | Isoform 1 of Collagen alpha-1(III) chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5286 | GSCDMVD | Isoform 2 of Uncharacterized protein C3orf67 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5288 | GSFPWQAKM | Haptoglobin isoform 2 preproprotein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5320 | GVFGGGTKL | Lambda-chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5347 | GYVSGWGRNA | Haptoglobin isoform 2 preproprotein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5348 | GYVSGWGRNANF | Haptoglobin isoform 2 preproprotein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5357 | HDLEEDTWYA | Haptoglobin isoform 2 preproprotein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5373 | HGVGDWGSTY | Prostaglandin D2 synthase 21kDa | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5381 | HLLPPPSEE | "cDNA FLJ14473 fis, clone MAMMA1001080, highly similar to Homo sapiens SNC73 protein (SNC73) mRNA" | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5400 | HVAHWNSAKY | Carbonic anhydrase 1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5403 | HVGDEDFVHL | Cystatin-B | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5422 | ICIFCCGCCH | Hepcidin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5424 | IDDAFARAF | Matrix metalloproteinase-9 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5437 | IEVDGRVYHV | Isoform 1 of Extracellular sulfatase Sulf-2 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5438 | IFGGGTKLTV | Ig lambda chain V-IV region Hil | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5496 | ILPVPAFNV | Isoform alpha-enolase of Alpha-enolase | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5497 | ILPVPAFNVI | Isoform alpha-enolase of Alpha-enolase | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5507 | INTFHQYSV | Protein S100-A9 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5516 | IQWENNGQVY | Lysyl oxidase homolog 1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5520 | IRVGGTGMF | Isoform 1 of Uromodulin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5521 | IRVGGTGMFT | Isoform 1 of Uromodulin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5526 | ISRLEPEDFA | IGKat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5527 | ISRLEPEDFA | IGKat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5528 | ISRLEPEDFA | similar to hCG1686089 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5610 | KLVDQNIFSF | Cathepsin D | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5611 | KLVNEVTEF | Isoform 1 of Serum albumin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5614 | KMYLGYEYV | Serotransferrin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5615 | KMYLGYEYVT | Serotransferrin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5617 | KQGFEPPSFV | Isoform 1 of Gelsolin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5622 | KSSVAS | "Isoform 2 of Microtubule-actin cross-linking factor 1, isoforms 1/2/3/5" | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5626 | KTYMLAFDV | Alpha-1-acid glycoprotein 1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5668 | KWGDAGAEYV | Glyceraldehyde-3-phosphate dehydrogenase | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5669 | KYICENQDSI | Isoform 1 of Serum albumin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5700 | LAVSQVVHKA | "cDNA FLJ35730 fis, clone TESTI2003131, highly similar to ALPHA-1-ANTICHYMOTRYPSIN" | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5704 | LAWDESLAPK | Neutrophil defensin 1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5713 | LCKDPVQEAW | Isoform M2 of Pyruvate kinase isozymes M1/M2 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5737 | LDTWDQVFV | Isoform 1 of Gelsolin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5748 | LEDWAGNEAY | Isoform 1 of Fibrinogen alpha chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5769 | LFFQGDREWF | Hemopexin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5770 | LFGDKLCTV | Isoform 1 of Serum albumin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5823 | LGQLGITKVF | Isoform 1 of Alpha-1-antitrypsin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5861 | LILRDTKTYM | Alpha-1-acid glycoprotein 1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5926 | LLQDFRVVAQ | Protein AMBP | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID5988 | LPTSWDWRNV | Dipeptidyl peptidase 1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6003 | LQDFRVVAQG | Protein AMBP | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6082 | LSVDDLVEKL | N-acetylglucosamine-6-sulfatase | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6083 | LSYPKDFTCV | Plasma protease C1 inhibitor | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6163 | MAEVDGTCY | "cDNA FLJ14473 fis, clone MAMMA1001080, highly similar to Homo sapiens SNC73 protein (SNC73) mRNA" | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6165 | MALQEACEAY | Histone H3.1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6167 | MALQEASEAY | Histone H3.2 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6172 | MDDYHFTSI | Myeloid cell nuclear differentiation antigen | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6175 | MENANVLARYA | Fructose-bisphosphate aldolase A | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6177 | MFETFNTPAM | "Actin, cytoplasmic 1" | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6179 | MFGIDRDAI | "cDNA FLJ54957, highly similar to Transketolase" | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6194 | MLLDTWDQVF | Isoform 1 of Gelsolin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6241 | MWDYFSQLSNNA | Apolipoprotein A-IV | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6254 | NDEKNWGLSV | Alpha-1-acid glycoprotein 1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6266 | NEVTEFAKTC | Isoform 1 of Serum albumin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6276 | NGDQYCGD | Putative uncharacterized protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6320 | NNWDVCADM | Retinol-binding protein 4 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6321 | NNWDVCADMV | Retinol-binding protein 4 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6343 | NVERVPFDAA | Isoform 1 of Gelsolin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6356 | NWIDSIIQR | Neutrophil elastase | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6360 | NWYVDGVEV | IGHat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6361 | NWYVDGVEV | Putative uncharacterized protein DKFZp686C11235 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6362 | NWYVDGVEV | Putative uncharacterized protein DKFZp686G11190 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6363 | NWYVDGVEV | Putative uncharacterized protein DKFZp686I04196 (Fragment) | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6364 | NWYVDGVEV | Putative uncharacterized protein DKFZp686O01196 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6365 | NWYVDGVEV | Putative uncharacterized protein DKFZp686P15220 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6366 | NWYVDGVEVH | IGHat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6367 | NWYVDGVEVH | Putative uncharacterized protein DKFZp686C11235 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6368 | NWYVDGVEVH | Putative uncharacterized protein DKFZp686G11190 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6369 | NWYVDGVEVH | Putative uncharacterized protein DKFZp686I04196 (Fragment) | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6370 | NWYVDGVEVH | Putative uncharacterized protein DKFZp686O01196 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6371 | NWYVDGVEVH | Putative uncharacterized protein DKFZp686P15220 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6372 | NWYVDGVEVHNA | IGHat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6373 | NWYVDGVEVHNA | Putative uncharacterized protein DKFZp686C11235 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6374 | NWYVDGVEVHNA | Putative uncharacterized protein DKFZp686G11190 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6375 | NWYVDGVEVHNA | Putative uncharacterized protein DKFZp686I04196 (Fragment) | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6376 | NWYVDGVEVHNA | Putative uncharacterized protein DKFZp686O01196 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6377 | NWYVDGVEVHNA | Putative uncharacterized protein DKFZp686P15220 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6383 | NYQRDGPMCM | Catalase | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6384 | NYVDWIKDTI | Protease serine 2 isoform B | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6414 | PNVDEHSVM | Isoform 2 of Filamin-A | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6415 | PNVDEHSVMT | Isoform 2 of Filamin-A | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6416 | PPAKPP | Glutamate [NMDA] receptor subunit epsilon-4 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6418 | PPEVKFNKPF | Isoform 1 of Alpha-1-antitrypsin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6424 | PPGKVV | Isoform 2 of Protein tyrosine phosphatase type IVA 3 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6431 | PPPPKA | Isoform 1 of Large proline-rich protein BAT2 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6433 | PPRDGFFGN | 66 kDa protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6434 | PQTDKCMTEQ | Prostaglandin D2 synthase 21kDa | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6540 | QKPGQAPRL | Ig kappa chain V-III region HAH | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6541 | QKPGQAPRL | IGKat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6542 | QKPGQAPRL | Putative uncharacterized protein ENSP00000374812 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6574 | QRIFENGYD | Neutrophil elastase | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6673 | RGWVTDGF | Apolipoprotein C-III | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6787 | SEFLKQAWF | Annexin A1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6788 | SEFLKQAWFI | Annexin A1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6789 | SEGLKLVDKF | Isoform 1 of Alpha-1-antitrypsin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6820 | SFSKDWSFY | Beta-2-microglobulin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6821 | SFSKDWSFYL | Beta-2-microglobulin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6826 | SFVNDIFERI | Histone H2B type 1-C/E/F/G/I | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6827 | SFVNDIFERI | Histone H2B type 1-K | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6828 | SFVNDIFERI | Histone H2B type 1-L | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6887 | SGTWYAMAK | Retinol-binding protein 4 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6943 | SIQDWVQKT | Haptoglobin isoform 2 preproprotein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6969 | SLFGGKPMII | Isoform 1 of Gelsolin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6975 | SLGQPNWDM | Leucine-rich alpha-2-glycoprotein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6978 | SLHLPKLSI | Isoform 1 of Alpha-1-antitrypsin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6988 | SLPLPNFSSL | Vimentin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID6999 | SLRAFQPFFV | Alpha-2-macroglobulin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7011 | SMVPNVGLKF | Bactericidal permeability-increasing protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7039 | SPGSGAGRPG | hypothetical protein XP_002342369 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7040 | SPGSGNARPN | Isoform 1 of Fibrinogen alpha chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7041 | SPGSGNARPNN | Isoform 1 of Fibrinogen alpha chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7091 | SSFLPWIRTT | Cathepsin G | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7103 | SSLKDYWSTV | Apolipoprotein C-III | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7185 | SVVETDYDQY | Prostaglandin D2 synthase 21kDa | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7186 | SVVETDYDQY | Prostaglandin-H2 D-isomerase | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7295 | SWYDNEFGY | Glyceraldehyde-3-phosphate dehydrogenase | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7319 | SYLDDEKNWG | Alpha-1-acid glycoprotein 2 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7327 | SYVFGTGTKV | 25 kDa protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7328 | SYVFGTGTKV | 25 kDa protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7334 | TAFCKAQGF | Prostaglandin D2 synthase 21kDa | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7335 | TAFCKAQGF | Prostaglandin-H2 D-isomerase | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7374 | TFEYPSNAVEEV | Isoform 2 of Inter-alpha-trypsin inhibitor heavy chain H4 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7394 | TGKWFYIAS | Alpha-1-acid glycoprotein 1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7395 | TGKWFYIAS | Alpha-1-acid glycoprotein 2 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7396 | TGKWFYIASA | Alpha-1-acid glycoprotein 1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7397 | TGKWFYIASA | Alpha-1-acid glycoprotein 2 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7431 | THTVPIYEGY | "Actin, cytoplasmic 1" | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7440 | TIGSLTG | Isoform 2 of Attractin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7445 | TISRLEPEDF | Ig kappa chain V-III region HAH | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7446 | TISRLEPEDF | IGKat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7447 | TISRLEPEDF | IGKat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7448 | TISRLEPEDF | similar to hCG1686089 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7452 | TKVVTG | Sodium-dependent proline transporter | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7459 | TLDGGFIYEA | "cDNA FLJ58679, highly similar to Lactotransferrin" | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7495 | TLINEQWLLT | Haptoglobin isoform 2 preproprotein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7506 | TLNRPFLFAV | Angiotensinogen | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7511 | TLQEFLKLA | Putative uncharacterized protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7554 | TNWDDMEKI | "Actin, cytoplasmic 1" | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7555 | TNWDDMEKI | "Actin, gamma-enteric smooth muscle" | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7563 | TSEAPFLHYL | Coronin-1A | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7571 | TSIQDWVQKT | Haptoglobin isoform 2 preproprotein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7693 | TYLPAVDEKL | Apolipoprotein C-II | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7699 | VAEFYGSKED | Serotransferrin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7713 | VATVLGT | Serum response factor | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7714 | VAWKADSSPV | hypothetical protein XP_002348153 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7715 | VAWKADSSPV | IGLat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7716 | VAWKADSSPV | IGLat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7759 | VDKFLEDVKK | Isoform 1 of Alpha-1-antitrypsin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7788 | VERVPFDAA | Isoform 1 of Gelsolin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7804 | VFGGGTKLTV | hypothetical protein XP_002348153 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7805 | VFGGGTKLTV | Ig lambda chain V-I region NEWM | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7806 | VFGGGTKLTV | IGLat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7807 | VFGGGTKLTV | IGLat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7808 | VFGGGTKLTV | IGLat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7809 | VFGGGTKLTV | IGLat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7810 | VFGGGTKLTV | Immunglobulin light chain variable region (Fragment) | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7811 | VFGGGTKLTV | Lambda-chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7812 | VFGGGTKLTV | Putative uncharacterized protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7822 | VFGGGTRLTV | IGLat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7852 | VHVGDEDFVH | Cystatin-B | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7860 | VKQGFEPPSF | Isoform 1 of Gelsolin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7915 | VLQSSGLYSL | IGHat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7916 | VLQSSGLYSL | Putative uncharacterized protein DKFZp686C11235 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7917 | VLQSSGLYSL | Putative uncharacterized protein DKFZp686G11190 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7918 | VLQSSGLYSL | Putative uncharacterized protein DKFZp686I04196 (Fragment) | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7919 | VLQSSGLYSL | Putative uncharacterized protein DKFZp686O01196 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7920 | VLQSSGLYSL | Putative uncharacterized protein DKFZp686P15220 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7962 | VNDIFERI | Histone H2B type 1-C/E/F/G/I | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7963 | VNDIFERI | Histone H2B type 1-K | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7964 | VNDIFERI | Histone H2B type 1-L | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7966 | VNIFHQYSV | Protein S100-A12 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7978 | VQNFAKEFV | Coactosin-like protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID7979 | VQNFAKEFVI | Coactosin-like protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID8070 | VVETDYDQYA | Prostaglandin D2 synthase 21kDa | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID8071 | VVETDYDQYA | Prostaglandin-H2 D-isomerase | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID8080 | VVFGGGTKL | IGLat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID8081 | VVFGGGTKL | IGLat protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID8082 | VVGQLKADED | Nuclear transport factor 2 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID8096 | VVSLGSRASL | Tumor necrosis factor ligand superfamily member 12 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID8109 | VYRQYTDSTF | Ceruloplasmin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID8111 | VYVLAS | FLJ00395 protein (Fragment) | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID8123 | WDFQGSTMLT | Vesicular integral-membrane protein VIP36 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID8140 | WKNFPSPVD | Hemopexin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID8141 | WKSNGAYNIF | Isoform 1 of Nidogen-1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID8153 | WLGNDYLHL | Isoform 1 of Fibrinogen alpha chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID8157 | WLSRDSSTW | Putative uncharacterized protein C4A | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID8176 | WQVKSGTIF | Calreticulin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID8179 | WSVDPLDRAM | Isoform 1 of Gelsolin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID8196 | WVPFDPAAQI | Zinc-alpha-2-glycoprotein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID8198 | WVPVTVEGY | Pepsin A | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID8242 | YDFGYDGD | Collagen alpha-2(I) chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID8243 | YDFGYDGDF | Collagen alpha-2(I) chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID8244 | YDFYPGKIDV | Zinc-alpha-2-glycoprotein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID8245 | YDGKGVGLGP | Collagen alpha-2(I) chain | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID8262 | YEDLRGSVTF | Polymeric immunoglobulin receptor | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID8263 | YEGYALPHAI | "Actin, cytoplasmic 1" | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID8264 | YEGYALPHAI | "Actin, gamma-enteric smooth muscle" | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID8268 | YEKYLGPQYV | "cDNA FLJ58679, highly similar to Lactotransferrin" | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID8270 | YELTQPLSV | V2-6 protein | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID8280 | YGFEKPSAI | Eukaryotic initiation factor 4A-III | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID8299 | YLDDEKNWG | Alpha-1-acid glycoprotein 2 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID8300 | YLDDEKNWGL | Alpha-1-acid glycoprotein 2 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID8321 | YMTKPDGTYI | Cytidine deaminase | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID8327 | YQGRLWAFCC | Neutrophil defensin 1 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID8365 | YSNEKPFTG | Isoform 1 of Mannan-binding lectin serine protease 2 | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID8381 | YTEFTPTEKD | Beta-2-microglobulin | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID8400 | YVVHTNYDE | Protein AMBP | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID8401 | YVVHTNYDEY | Protein AMBP | Urine | NA | Nano-LC-MS | Ovarian cancer | Uniquely present in case of urine of ovarian cancer patients | 24982608 |
CancerPDF_ID8507 | DFLAEGGGVR | Fibrinogen alpha | Serum | 1019.5 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
CancerPDF_ID8510 | GDFLAEGGGV | Fibrinogen alpha | Serum | 920.42 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
CancerPDF_ID8511 | DFLAEGGGV | Fibrinogen alpha | Serum | 863.4 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
CancerPDF_ID8512 | FLAEGGGV | Fibrinogen alpha | Serum | 748.38 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
CancerPDF_ID8513 | FLAEGGG | Fibrinogen alpha | Serum | 649.31 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
CancerPDF_ID8514 | DFLAEGG | Fibrinogen alpha | Serum | 707.31 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
CancerPDF_ID8545 | SKITHRIHWE | Complement C3f | Serum | 1305.69 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
CancerPDF_ID8549 | THRIHWE | Complement C3f | Serum | 977.48 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
CancerPDF_ID8551 | IHWESASLL | Complement C3f | Serum | 1054.54 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
CancerPDF_ID8552 | HWESASLL | Complement C3f | Serum | 941.46 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
CancerPDF_ID8553 | HWESASLL | Complement C3f | Serum | 955.48 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
CancerPDF_ID8554 | HWESASL | Complement C3f | Serum | 828.38 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
CancerPDF_ID8555 | ASHLGLA | Complement C3f | Serum | 667.37 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
CancerPDF_ID8559 | SHALQLNN | Complement C3f | Serum | 895.45 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
CancerPDF_ID8573 | PGPPDVPDHA | Inter-alpha-trypsin inhibitor heavy chain H4 | Serum | 1000.46 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
CancerPDF_ID8574 | GPPDVPDHA | Inter-alpha-trypsin inhibitor heavy chain H4 | Serum | 903.41 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
CancerPDF_ID8575 | GPPDVPDH | Inter-alpha-trypsin inhibitor heavy chain H4 | Serum | 832.37 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
CancerPDF_ID8605 | VVTNPKE | Prealbumin | Serum | 785.43 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
CancerPDF_ID8611 | MGRVYDPRA | C1-inhibitor | Serum | 1063.52 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
CancerPDF_ID8613 | SEMVVAGKLQ | Inter- trypsin inhibitor heavy chain H4 (ITIH4) precursor | Serum | 1061.09 | MALDI-TOF | Breast cancer | Upregulated in cancer as compare to normal control with fold change of 1.6 | 26705257 |
CancerPDF_ID8621 | VELGTQPATQ | Apolipoprotein A-II precursor | Serum | 1041.25 | MALDI-TOF | Breast cancer | Downregulated in cancer as compare to normal control with fold change of 1.8 | 26705257 |
CancerPDF_ID8631 | RPPGFSPF | "kininogen L,high MW" | Plasma | 904.53 | MALDI-TOF | Cervical cancer | Uniquely present in cervical cancer | 24416269 |
CancerPDF_ID8676 | ADGRAHRGPA | "Isoform 4 of Spectrin beta chain, brain 3" | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8696 | AKVQPYLDD | Apolipoprotein A-I | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8697 | AKVQPYLDDF | Apolipoprotein A-I | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8699 | ALGCLVKDY | Putative uncharacterized protein DKFZp686N02209 | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8703 | APDNLDPIPK | Inter-alpha (Globulin) inhibitor H2 | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8721 | AVETEPEPEL | Apolipoprotein E | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8735 | DCLGCVHPIS | Isoform LMW of Kininogen-1 | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8737 | DCREPFLSC | Complement C4-A | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8738 | DCREPFLSCC | Complement C4-A | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8741 | DDKVYPGEQY | Ceruloplasmin | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8742 | DDLQDFLSKD | Inter-alpha (Globulin) inhibitor H2 | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8745 | DELFQDRFF | Isoform 1 of Clusterin | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8746 | DFNSYVRV | Complement C4-A | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8749 | DGDFNSYVRV | Complement C4-A | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8750 | DKLGEVNTYA | Apolipoprotein A-IV | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8758 | DLGEENFKA | Putative uncharacterized protein ALB | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8763 | DMEDVCGRLV | Apolipoprotein E | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8764 | DNENVVNEY | Fibrinogen beta chain | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8765 | DNWDSVTST | Apolipoprotein A-I | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8766 | DNWDSVTSTF | Apolipoprotein A-I | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8769 | DPAKLDQIES | Inter-alpha (Globulin) inhibitor H2 | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8777 | DTEEEDFHVD | Isoform 1 of Alpha-1-antitrypsin | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8783 | DYSLMKDPVA | Isoform 2 of Phospholipid transfer protein | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8784 | EDIPPADLSD | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8794 | EKLSPLGEEM | Apolipoprotein A-I | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8796 | ELPAILHTEL | Angiotensinogen | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8803 | ENGGARLAEY | Apolipoprotein A-I | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8804 | ENPMRFSCQ | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8808 | EQLGPVTQEF | Apolipoprotein A-I | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8817 | EVILPVPAF | Isoform alpha-enolase of Alpha-enolase | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8823 | FCKILGPLS | Lumican | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8824 | FDKSCAVAEY | Haptoglobin | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8827 | FDVSSFNPHG | Serum paraoxonase/arylesterase 1 | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8830 | FISLGEAC | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8833 | FLGPIIKAE | Ceruloplasmin | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8836 | FPEVDVLTKY | Apolipoprotein B-100 | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8847 | FTELDVAAEK | Angiotensinogen | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8850 | FTVNFGDTEE | Isoform 1 of Alpha-1-antitrypsin | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8854 | FVELGTQPAT | Apolipoprotein A-II | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8856 | FVTADKFDEN | Phosphoglycerate kinase 1 | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8860 | GDLWVGCHPN | Serum paraoxonase/arylesterase 1 | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8872 | GIVTNWDDME | "Actin, cytoplasmic 1" | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8879 | GLIGPLIVCR | Ceruloplasmin | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8881 | GLPRSVRPI | Isoform 1 of Gastrin/cholecystokinin type B receptor | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8905 | GQYCYELDEK | Vitronectin | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8906 | GRDGAIDLGY | apolipoprotein F precursor | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8927 | GYLCLPKTA | Isoform 1 of EGF-containing fibulin-like extracellular matrix protein 1 | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8932 | HFSVIDFNQN | Inter-alpha (Globulin) inhibitor H2 | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8938 | HKALYCEL | Serum paraoxonase/arylesterase 1 | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8941 | HLSFLEKDL | Apolipoprotein A-IV | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8950 | IDDIDVRF | Apolipoprotein B-100 | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8951 | IDDIDVRFQ | Apolipoprotein B-100 | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8953 | IDVACHPGY | Isoform 1 of Complement factor H | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8961 | IINTFHQY | Protein S100-A9 | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8962 | IITKFLENED | Isoform 1 of Alpha-1-antitrypsin | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8963 | IITTPPLKDF | Apolipoprotein B-100 | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8965 | ILDDLRAED | Inter-alpha (Globulin) inhibitor H2 | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8983 | IQLTYNPDES | Isoform Gamma-B of Fibrinogen gamma chain | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8993 | IVTNWDDME | "Actin, cytoplasmic 1" | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8994 | IVTNWDDMEK | "Actin, cytoplasmic 1" | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID8998 | KITPNLAEF | Isoform 1 of Alpha-1-antitrypsin | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9002 | KNSIYDPLPT | geranylgeranyl diphosphate synthase 1 isoform B | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9008 | KVQPYLDDF | Apolipoprotein A-I | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9010 | LDDFQKKW | Apolipoprotein A-I | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9012 | LDNWDSVTST | Apolipoprotein A-I | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9016 | LEPLDGKLAS | dynactin 1 isoform 4 | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9018 | LGCLVKDY | Putative uncharacterized protein DKFZp686N02209 | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9025 | LGSDVRVPSY | Apolipoprotein B-100 | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9028 | LGYEYVTAIR | Serotransferrin | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9035 | LLDNWDSVTS | Apolipoprotein A-I | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9043 | LLYCDLPEPR | Serotransferrin | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9044 | LNAVPTKEM | Putative uncharacterized protein ACY1 | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9048 | LPGPPDVPDH | Isoform 1 of Inter-alpha-trypsin inhibitor heavy chain H4 | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9053 | LPSLELPVLH | Apolipoprotein B-100 | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9061 | LVRPGTALEL | Isoform DPI of Desmoplakin | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9064 | LYDATYETKE | Cofilin-1 | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9074 | MPICLPSKDY | Haptoglobin | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9083 | NCGPPPTLSF | C4b-binding protein alpha chain | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9089 | NIMEILRGD | Isoform 1 of Fibrinogen alpha chain | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9090 | NIMEILRGDF | Isoform 1 of Fibrinogen alpha chain | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9095 | NIRVLDPFT | "cDNA FLJ54957, highly similar to Transketolase" | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9099 | NLDVSLQLPS | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9100 | NLGLLDPNS | Inter-alpha (Globulin) inhibitor H2 | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9104 | NLKLLDNWD | Apolipoprotein A-I | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9105 | NLKLLDNWDS | Apolipoprotein A-I | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9109 | NNLGLLDPNS | Inter-alpha (Globulin) inhibitor H2 | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9116 | NPYYYVDGD | Isoform 1 of Inter-alpha-trypsin inhibitor heavy chain H3 | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9119 | NSLFEYQKNN | Isoform 1 of Fibrinogen alpha chain | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9124 | NVVIACLVQG | SNC66 protein | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9128 | NYPHTSVTDV | Inter-alpha (Globulin) inhibitor H2 | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9133 | PAVSRVMN | Isoform 1 of Inter-alpha-trypsin inhibitor heavy chain H4 | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9143 | QAEAKSYFEK | Apolipoprotein A-II | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9147 | QAMDIHFH | Isoform 1 of Clusterin | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9169 | QIDDIDVRF | Apolipoprotein B-100 | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9170 | QKDSYVGDEA | "Actin, aortic smooth muscle" | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9171 | QKIGDNLREL | Apolipoprotein A-IV | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9173 | QKKWQEEMEL | Apolipoprotein A-I | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9177 | QKVEPLRAEL | Apolipoprotein A-I | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9180 | QKVPTADLED | Isoform 1 of Vitamin D-binding protein | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9181 | QLTYNPDES | Isoform Gamma-B of Fibrinogen gamma chain | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9195 | QTVTDYGKDL | Apolipoprotein A-II | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9205 | QYDCLGCVHP | Isoform LMW of Kininogen-1 | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9210 | RFISLGEAC | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9218 | SDGRLPFF | "Bone morphogenetic protein 1 isoform 1, variant (Fragment)" | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9222 | SDVRVPSYT | Apolipoprotein B-100 | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9232 | SHDELPRTFQ | Apolipoprotein B-100 | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9236 | SILGSDVRVP | Apolipoprotein B-100 | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9259 | SPPDSHVLLA | Alpha-2-HS-glycoprotein | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9266 | SPYEPLNFH | Isoform 1 of Clusterin | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9284 | TDKIIEVEE | Isoform D of Fibulin-1 | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9288 | TEDAVDAERL | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9294 | TGILSFDKSC | Haptoglobin | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9296 | TGTWNPGSSE | Isoform 1 of Fibrinogen alpha chain | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9298 | THDIITKFL | Isoform 1 of Alpha-1-antitrypsin | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9307 | TLRETYGEM | Putative uncharacterized protein ALB | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9308 | TLSLPELEQ | Apolipoprotein A-IV | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9309 | TLSVVTMYH | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9325 | TQEFWDNLE | Apolipoprotein A-I | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9326 | TQEFWDNLEK | Apolipoprotein A-I | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9328 | TRFISLGEAC | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9333 | TTMYPGIADR | "Actin, aortic smooth muscle" | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9336 | TVDQVKDLYS | Ceruloplasmin | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9340 | TVNFGDTEE | Isoform 1 of Alpha-1-antitrypsin | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9345 | TVTDYGKDL | Apolipoprotein A-II | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9346 | TVTDYGKDLM | Apolipoprotein A-II | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9350 | TVYVDVLKD | Apolipoprotein A-I | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9351 | TWQDCEYKDA | Isoform LMW of Kininogen-1 | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9361 | VFLDCCNY | Complement C3 (Fragment) | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9371 | VGGRLAGCGV | AMT protein | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9374 | VKELDRDTVF | Isoform 1 of Alpha-1-antitrypsin | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9379 | VLFCLSEDK | Cofilin-1 | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9399 | VPFDAATLH | Isoform 1 of Gelsolin | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9401 | VPLLGEEEH | Matrix-remodeling-associated protein 5 | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9408 | VTDYGKDLME | Apolipoprotein A-II | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9411 | VTQEFWDNLE | Apolipoprotein A-I | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9418 | VVMAEVDGTC | SNC66 protein | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9421 | VVTRSRR | Isoform 1 of Microtubule-associated protein 6 | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9423 | VYVDVLKDS | Apolipoprotein A-I | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9426 | WDNLEKETEG | Apolipoprotein A-I | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9439 | YKTLYTLDAS | Isoform 2 of Transmembrane glycoprotein NMB | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
CancerPDF_ID9450 | RPPGFSPF | Des-Arg9 Bradykinin | Plasma | 904.46 | MALDI-TOF | Colorectal cancer | Higher median intensity for liver metastasis group and lower median intensity for adenoma and CRC groups than the controls. | 26379225 |
CancerPDF_ID9453 | SHALQLNNR | Complement C4-A/Complement C4-B | Plasma | 1052.56 | MALDI-TOF | Colorectal cancer | "Intensity was similar to controls, controversially, in adenoma and CRC groups was highest. " | 26379225 |
CancerPDF_ID9454 | RPPGFSPFR | Bradykinin | Plasma | 1060.57 | MALDI-TOF | Colorectal cancer | Higher median intensity for liver metastasis group and lower median intensity for adenoma and CRC groups than the controls. | 26379225 |
CancerPDF_ID9455 | RPPGFSPFR | oxidated Bradykinin | Plasma | 1076.56 | MALDI-TOF | Colorectal cancer | Higher median intensity for liver metastasis group and lower median intensity for adenoma and CRC groups than the controls. | 26379225 |
CancerPDF_ID9456 | HWESASLLR | Complement C3 | Plasma | 1098.57 | MALDI-TOF | Colorectal cancer | "Lower intensity in control, adenoma, early,late CRC and much more lower in liver metastasis group." | 26379225 |
CancerPDF_ID9457 | THRIHWESA | Complement C3 | Plasma | 1136.57 | MALDI-TOF | Colorectal cancer | "Expression levels similar for liver metastasis and controls, but for adenoma and CRC groups was higher than controls." | 26379225 |
CancerPDF_ID9458 | LQLNNRQIR | Complement C4-A/Complement C4-B | Plasma | 1154.68 | MALDI-TOF | Colorectal cancer | "Intensity was similar to controls, controversially, in adenoma and CRC groups was highest. " | 26379225 |
CancerPDF_ID9459 | IHWESASLLR | Complement C3 | Plasma | 1211.65 | MALDI-TOF | Colorectal cancer | Lower intensity in liver metastasis than control groups and an opposite trend in adenoma and CRC group. | 26379225 |
CancerPDF_ID9460 | ALQLNNRQIR | Complement C4-A/Complement C4-B | Plasma | 1225.72 | MALDI-TOF | Colorectal cancer | "Intensity was similar to controls, controversially, in adenoma and CRC groups was highest. " | 26379225 |
CancerPDF_ID9461 | ITHRIHWESA | Complement C3 | Plasma | 1249.65 | MALDI-TOF | Colorectal cancer | "Expression levels similar for liver metastasis and controls, but for adenoma and CRC groups was higher than controls." | 26379225 |
CancerPDF_ID9463 | RHDWGHEKQR | Kininogen-1 | Plasma | 1348.63 | MALDI-TOF | Colorectal cancer | Not significant in annova test | 26379225 |
CancerPDF_ID9495 | KVVNPTQK | Alpha-1-antitrypsin | Serum | 457.26 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9496 | GKVVNPTQK | Alpha-1-antitrypsin | Serum | 485.78 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9497 | MGKVVNPTQK | Alpha-1-antitrypsin | Serum | 551.29 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9498 | MGKVVNPTQK | Alpha-1-antitrypsin | Serum | 559.3 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9520 | PVELLVAES | Alpha-1B-glycoprotein | Serum | 478.75 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9521 | YESDVMGR | Alpha-2-macroglobulin | Serum | 478.7 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9524 | HPNSPLDEEN | Alpha-1-antichymotrypsin | Serum | 576.26 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9532 | QTLPPLNN | RAC-beta serine/threonine-protein kinase | Serum | 448.73 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9533 | VAASQAALGL | Serum albumin | Serum | 450.75 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9537 | DAHKSEVAHR | Serum albumin | Serum | 575.27 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9544 | GDEELLRFSN | Protein AMBP | Serum | 590.28 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9552 | EEYTKKLNTQ | Apolipoprotein A-I | Serum | 627.34 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9554 | HLDQQVEEF | Apolipoprotein A-IV | Serum | 572.77 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9593 | TALELEEA | Uncharacterized protein C2orf27 | Serum | 438.2 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9594 | EARLVESN | Coiled-coil domain-containing protein 11 | Serum | 459.23 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9596 | TPWSLARPQG | Complement factor B | Serum | 556.79 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9597 | IHWESASLL | Complement C3 | Serum | 528.26 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9598 | LDVSLQLPSR | Complement C3 | Serum | 564.34 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9599 | IHWESASLLR | Complement C3 | Serum | 404.55 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9606 | HWESASLL | Complement C3 | Serum | 471.73 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9609 | SVQLTEK | Complement C3 | Serum | 402.71 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9613 | HALQLNN | Complement C4-A | Serum | 405.2 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9614 | SHALQLNN | Complement C4-A | Serum | 448.72 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9615 | EEELQFSLGS | Complement C4-A | Serum | 569.76 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9617 | GLEEELQFS | Complement C4-B | Serum | 526.24 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9629 | DLMVPLGP | Cullin-9 | Serum | 421.2 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9630 | QNTAIREEL | Cytospin-A | Serum | 537.26 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9631 | VGSLPGTNPA | Chromosome transmission fidelity protein 8 homolog isoform 2 | Serum | 456.72 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9632 | EGGFTATGQR | Extracellular matrix protein 1 | Serum | 512.24 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9633 | CLMPAVQNW | HERV-K_3q21.2 provirus ancestral Env polyprotein | Serum | 531.28 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9647 | SGEVSHPRKT | Alpha-2-HS-glycoprotein | Serum | 549.28 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9650 | SPSGEVSHPR | Alpha-2-HS-glycoprotein | Serum | 526.76 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9653 | DFLAEGGGV | Fibrinogen alpha chain | Serum | 432.69 | LC-MS | Lung adenocarcinoma | Differentially expressed between Lung cancer vs control | 21533267 |
CancerPDF_ID9654 | GDSTFESKS | Fibrinogen alpha chain | Serum | 479.21 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9655 | DFLAEGGGVR | Fibrinogen alpha chain | Serum | 510.74 | LC-MS | Lung adenocarcinoma | Differentially expressed between Lung cancer vs control | 21533267 |
CancerPDF_ID9658 | TSSTSYNRGD | Fibrinogen alpha chain | Serum | 544.23 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9660 | GDSTFESKSY | Fibrinogen alpha chain | Serum | 560.73 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9714 | GDSTFESK | Fibrinogen alpha chain | Serum | 435.69 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9715 | FLAEGGGVR | Fibrinogen alpha chain | Serum | 453.25 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9716 | GDFLAEGGGV | Fibrinogen alpha chain | Serum | 461.21 | LC-MS | Lung adenocarcinoma | Differentially expressed between Lung cancer vs control | 21533267 |
CancerPDF_ID9717 | DSTFESKSY | Fibrinogen alpha chain | Serum | 532.24 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9718 | SSSYSKQFTS | Fibrinogen alpha chain | Serum | 561.25 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9729 | SSSYSKQF | Fibrinogen alpha chain | Serum | 467.22 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9765 | NEEGFFSA | Fibrinogen beta chain | Serum | 450.68 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9766 | NDNEEGFFSA | Fibrinogen beta chain | Serum | 565.21 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9767 | KVVPNNDK | Filamin-C | Serum | 457.27 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9768 | ESPASPSE | Fos-related antigen 2 | Serum | 402.18 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9771 | STLVTER | ARF GTPase-activating protein GIT1 | Serum | 403.22 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9773 | ALAHKYH | Hemoglobin subunit beta | Serum | 420.22 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9774 | LGGHLDAK | Haptoglobin | Serum | 405.72 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9779 | LGGHLDAKG | Haptoglobin-related protein | Serum | 434.22 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9780 | ILGGHLDAK | Haptoglobin-related protein | Serum | 462.26 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9781 | ILGGHLDAKG | Haptoglobin-related protein | Serum | 490.76 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9782 | KPKNPANPVQ | Haptoglobin-related protein | Serum | 546.8 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9786 | EVQLVESG | Ig heavy chain V-III region BRO | Serum | 430.72 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9790 | EVQLVESGG | Ig heavy chain V-III region BRO | Serum | 459.23 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9795 | TQKSLSLSPG | Ig gamma-2 chain C region | Serum | 509.27 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9798 | PGPPDVPDH | Inter-alpha-trypsin inhibitor heavy chain H4 | Serum | 465.7 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9799 | PGVLSSRQL | Inter-alpha-trypsin inhibitor heavy chain H4 | Serum | 478.77 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9800 | PGPPDVPDHA | Inter-alpha-trypsin inhibitor heavy chain H4 | Serum | 501.23 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9801 | LPGPPDVPDH | Inter-alpha-trypsin inhibitor heavy chain H4 | Serum | 522.25 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9817 | SEMVVAGKLQ | Inter-alpha-trypsin inhibitor heavy chain H4 | Serum | 531.28 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9826 | GPGGYPGGIH | "Keratin, type II cytoskeletal 2 epidermal" | Serum | 456.23 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9830 | SGFSSVSVSR | "Keratin, type II cytoskeletal 6A" | Serum | 506.75 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9833 | SGFSSISVSR | "Keratin, type II cytoskeletal 6C" | Serum | 513.75 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9835 | DDDLEHQ | Kininogen-1 | Serum | 436.16 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9836 | DDDLEHQGGH | Kininogen-1 | Serum | 561.72 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9843 | ELDKWAKI | Kynureninase | Serum | 501.75 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9845 | FLLSLVLT | Limbin | Serum | 453.26 | LC-MS | Lung adenocarcinoma | Differentially expressed between Lung cancer vs control | 21533267 |
CancerPDF_ID9847 | DGVNTVTVPG | MACRO domain-containing protein 2 | Serum | 479.76 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9848 | AINGSGNAENR | "Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 3" | Serum | 551.76 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9851 | NSRSAVVEL | Nucleus accumbens-associated protein 1 | Serum | 487.77 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9854 | MFLSDNPN | Niemann-Pick C1 protein | Serum | 477.18 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9855 | KEQENRKGL | Protein DJ-1 | Serum | 551.3 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9857 | VSSGATALRN | Plakophilin-4 | Serum | 488.24 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9858 | ICCIAEVLIT | PMS1 protein homolog 1 | Serum | 539.25 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9859 | FLPLGLALGL | Prostasin | Serum | 507.29 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9861 | DIQGQQSLRL | Ras association domain-containing protein 8 | Serum | 579.29 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9862 | EMAEDPLT | Rho-related BTB domain-containing protein 2 | Serum | 453.23 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9881 | TSIEMAEG | Serine/threonine-protein kinase 3 | Serum | 419.17 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9889 | SLEDKTERE | Prothrombin | Serum | 553.77 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9899 | TAVVTNPKE | Transthyretin | Serum | 479.76 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9900 | TTAVVTNPKE | Transthyretin | Serum | 530.27 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
CancerPDF_ID9924 | QRPPPPP | Basic salivary proline-rich protein 4 | Saliva | 771.4 | MALDI-TOF | Head and neck cancer | Differentially expressed between Head and neck cancer vs control groups | 20879038 |
CancerPDF_ID9935 | RPPGFSPFR | Kininogen-1 | Serum | NA | LC-MS | Breast cancer | Differentially expressed between cancer vs control | 21124649 |
CancerPDF_ID9936 | RPPGFSPFR | Kininogen-1 | Serum | NA | LC-MS | Breast cancer | Differentially expressed between cancer vs control | 21124649 |
CancerPDF_ID9937 | RPPGFSPF | Kininogen-1 | Serum | NA | LC-MS | Breast cancer | NA | 21124649 |
CancerPDF_ID9954 | SFSKDWSF | Beta-2-microglobulin | Urine | 1003.4501 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID9955 | QKAREDIF | Zinc-alpha-2-glycoprotein | Urine | 1006.5155 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID9956 | DVSLQLPSR | Complement C3 | Urine | 1014.5541 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID9957 | HALSKYGAAT | Alpha-2-macroglobulin | Urine | 1018.5306 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID9958 | FRLLGNVLV | Hemoglobin subunit beta | Urine | 1030.638 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID9959 | QGLLLLDFGG | Hermansky-Pudlak syndrome 6 protein | Urine | 1032.6155 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID9960 | RVLGKDCNE | Band 4.1-like protein 4A | Urine | 1033.5446 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID9961 | RTERGRKM | Myosin-4 | Urine | 1033.5371 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID9962 | SKDWSFYL | Beta-2-microglobulin | Urine | 1045.5074 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID9963 | VNCLSDLVGQ | Nesprin-1 | Urine | 1047.5336 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID9964 | SGSVIDQSRV | Uromodulin | Urine | 1047.5336 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID9965 | VVYPWTQR | Hemoglobin subunit beta | Urine | 1048.5583 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID9966 | LNNFYPRE | Ig kappa chain C region | Urine | 1052.5468 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID9967 | GPKWPEPVF | Mannan-binding lectin serine protease 2 | Urine | 1056.5455 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID9968 | RPPGFSPFR | Kininogen-1 | Urine | 1060.5946 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID9969 | FKAWAVARL | Serum albumin precursor | Urine | 1061.6096 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID9970 | KSQVVAGTNY | Cystatin-B | Urine | 1066.5416 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID9971 | GHVLAKELEA | Insulin-like growth factor II | Urine | 1066.6003 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID9972 | GLDPGLDHML | "Alpha-aminoadipic semialdehyde synthase, mitochondrial" | Urine | 1067.4723 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID9973 | GEYKFQNAL | Serum albumin precursor | Urine | 1069.5603 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID9974 | IQRTPKIQV | Beta-2-microglobulin | Urine | 1082.6496 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID9975 | YGRAPQLRE | Protein AMBP | Urine | 1089.568 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID9976 | PITFGQGTRL | Ig kappa chain V-II region TEW | Urine | 1089.5879 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID9977 | YRSPHWGST | Prostaglandin-H2 D-isomerase | Urine | 1090.4961 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID9978 | FVLKTPSAAY | Gelsolin | Urine | 1096.6118 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID9979 | PILRHGIQY | Kininogen-1 | Urine | 1096.616 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID9980 | FSSPHGKDLL | Serotransferrin precursor | Urine | 1100.5738 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID9982 | MGKVVNPTQK | Alpha-1-antitrypsin | Urine | 1101.5892 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID9985 | ISRLEPEDF | Ig kappa chain V-III region NG9 (Fragment) | Urine | 1105.5325 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID9986 | RLLHVAVSDV | 26S proteasome non-ATPase regulatory subunit 1 | Urine | 1108.5962 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID9987 | RPEVHSKEQ | Zinc finger protein 397OS | Urine | 1109.5634 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID9988 | SQRFPKAEF | Serum albumin precursor | Urine | 1109.5951 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID9989 | PRYPVGKFF | Insulin-like growth factor II | Urine | 1110.5979 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID9990 | RAHGQESAIF | Secreted and transmembrane protein 1 | Urine | 1115.5425 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID9991 | LSFSKDWSF | Beta-2-microglobulin | Urine | 1116.5437 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID9992 | AKLYGRAPQL | Protein AMBP | Urine | 1116.6341 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID9995 | ITKQKWEAE | Zinc-alpha-2-glycoprotein | Urine | 1132.591 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID9998 | YVVHTNYDE | Protein AMBP | Urine | 1139.4901 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10003 | RVAPEEHPVL | "Actin, cytoplasmic 1" | Urine | 1146.6317 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10004 | LAAWQELCQS | Conserved oligomeric Golgi complex subunit 7 | Urine | 1148.4899 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10005 | WRQVEGMED | Zinc-alpha-2-glycoprotein | Urine | 1149.4816 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10006 | DVNKYLGRW | Apolipoprotein D | Urine | 1150.6011 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10010 | KIRPFFPQQ | Fibrinogen beta chain | Urine | 1160.6606 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10011 | LVVYPWTQR | Hemoglobin subunit beta | Urine | 1161.6392 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10012 | KQRNFDKIL | Myosin-2 | Urine | 1161.6557 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10014 | AFRQGHNSVF | Hemopexin | Urine | 1162.5769 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10015 | YARRHPDYS | Serum albumin precursor | Urine | 1164.5616 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10016 | RNVEVIMCVC | Dedicator of cytokinesis protein 2 | Urine | 1165.4962 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10017 | ERIRERSKP | Matrix Gla protein | Urine | 1170.6794 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10018 | YGSKEDPQTF | Serotransferrin precursor | Urine | 1171.5517 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10020 | QQDKFLGRW | Prostaglandin-H2 D-isomerase | Urine | 1177.6029 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10021 | LRVLRAQPVQ | Gelsolin | Urine | 1179.7158 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10022 | GEYKFQNALL | Serum albumin precursor | Urine | 1182.6102 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10023 | VKHSTIFENL | Serotransferrin precursor | Urine | 1187.6475 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10024 | LAVRYSRGRL | Vesicular integral-membrane protein VIP36 | Urine | 1190.6974 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10025 | VVYPWTQRF | Hemoglobin subunit beta | Urine | 1195.629 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10026 | YEKTDTDGKF | Protein AMBP | Urine | 1203.5398 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10028 | VRWLQGSQEL | Ig alpha-2 chain C region | Urine | 1215.6412 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10032 | VDETYVPKEF | Serum albumin precursor | Urine | 1226.5773 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10035 | YVIIKPLVWV | Serum amyloid P-component | Urine | 1229.7657 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10038 | RKPQYEQLTA | "Bullous pemphigoid antigen 1, isoforms 6/9/10" | Urine | 1233.6192 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10040 | WKYYYDGKD | Zinc-alpha-2-glycoprotein | Urine | 1237.5395 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10043 | PTTKTYFPHF | Hemoglobin subunit alpha | Urine | 1238.623 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10044 | PRYPVGKFFQ | Insulin-like growth factor II | Urine | 1238.6583 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10047 | VNWIDSIIQR | Leukocyte elastase | Urine | 1243.6792 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10049 | YRSPHWGSTY | Prostaglandin-H2 D-isomerase | Urine | 1253.5665 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10050 | FWLGNEKIHL | Fibrinogen gamma chain precursor | Urine | 1256.6718 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10056 | SFSKDWSFYL | Beta-2-microglobulin | Urine | 1279.601 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10063 | DRVYIHPFHL | Angiotensinogen | Urine | 1296.6753 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10064 | TYVPKEFNAET | Serum albumin precursor | Urine | 1298.6345 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10070 | LVVYPWTQRF | Hemoglobin subunit beta | Urine | 1308.6826 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10075 | PWLKKIMDRM | Protein AMBP | Urine | 1317.7008 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10079 | FKGKWERPFE | Alpha-1-antitrypsin | Urine | 1323.6605 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10101 | VWKSHKWDRE | Hemopexin | Urine | 1370.6835 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10733 | IAFAQY | Serum albumin precursor | Urine | 712.3755 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10734 | PSLAADF | Serum albumin precursor | Urine | 720.3502 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10735 | FHDDGF | Basement membrane-specific heparan sulfate proteoglycan core protein | Urine | 737.3013 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10736 | FKVSFL | Apolipoprotein A-I | Urine | 740.4406 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10737 | LAEGGGVR | Fibrinogen alpha chain | Urine | 758.4169 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10738 | TNDSVSF | Extracellular sulfatase Sulf-2 | Urine | 769.353 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10739 | FFKGEF | Hemopexin | Urine | 774.387 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10740 | FRVVAQG | Protein AMBP | Urine | 776.4269 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10741 | PSLGAVQI | Cyclic AMP-dependent transcription factor ATF-6 beta | Urine | 784.4338 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10742 | YGRAPQL | Protein AMBP | Urine | 804.424 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10743 | PPGFPPPP | Pre-mRNA 3'-end-processing factor FIP1 | Urine | 805.4618 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10744 | IAFAQYL | Serum albumin precursor | Urine | 825.4551 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10745 | VKHSTIF | Serotransferrin precursor | Urine | 831.4815 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10746 | DRITGKW | Alpha-1-acid glycoprotein 2 | Urine | 875.4532 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10747 | HTFTFPQ | MAX gene-associated protein | Urine | 877.453 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10748 | LNLGPITR | Uromodulin | Urine | 883.5165 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10749 | LVSLIGAMI | Putative sodium-coupled neutral amino acid transporter 9 | Urine | 916.5636 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10750 | ERMFLSF | Hemoglobin subunit alpha | Urine | 929.4521 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10751 | VCTPLGLAR | Protein LMBR1L | Urine | 929.4898 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10752 | DQSPPPPPP | Retinoblastoma-like protein 2 | Urine | 931.4513 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10753 | LKGEVSDAL | Interferon-induced protein with tetratricopeptide repeats 1-like protein | Urine | 931.4936 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10754 | FRLLGNVL | Hemoglobin subunit beta | Urine | 931.5745 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10755 | FHVDQVTT | Alpha-1-antitrypsin | Urine | 946.4686 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10756 | FVHEPLVD | Ribonuclease pancreatic | Urine | 955.4758 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10757 | RVREPVIS | Titin | Urine | 955.5656 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10758 | ESFKVSFL | Apolipoprotein A-I | Urine | 956.5084 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10759 | FSHVNIKL | Secreted and transmembrane protein 1 | Urine | 957.5455 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10760 | PRYPVGKF | Insulin-like growth factor II | Urine | 963.52 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10761 | WVFGGGTKL | Ig lambda chain V-VI region NIG-48 PE=1 SV=1 | Urine | 964.5108 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10762 | TVLTSKYR | Hemoglobin subunit alpha | Urine | 967.5594 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10763 | VLNLGPITR | Uromodulin | Urine | 982.6002 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10764 | KQTYLNQT | Low-density lipoprotein receptor-related protein 5 | Urine | 995.5532 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID10778 | KRPPGFSPFR | Kininogen-1 | Urine | 1204.6522 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
CancerPDF_ID11136 | AAAALPGAR | PR domain zinc finger protein 13 | Serum | NA | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11137 | AAAATVREL | Conserved oligomeric Golgi complex subunit 5 (Fragment) | Serum | NA | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11138 | AAAEARHEV | Multimerin-2 | Serum | 952.47264 | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11139 | AAAEEEKVL | A-kinase anchor protein 12 | Serum | NA | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11140 | AAAEITRKL | Nucleolar protein 56 | Serum | NA | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11141 | AAAETEKQV | FH1/FH2 domain-containing protein 1 | Serum | 945.47673 | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11142 | AAAGHMKLV | Protein TANC1 | Serum | NA | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11143 | AAAGITRNV | Receptor expression-enhancing protein 6 | Serum | NA | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11144 | AAAGQIHHV | Serine palmitoyltransferase 2 | Serum | 902.47225 | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11145 | AAAHGPHAL | Cbp/p300-interacting transactivator 4 | Serum | 843.43514 | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11146 | AAAKALRI | Double-stranded RNA-binding protein Staufen homolog 1 | Serum | NA | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11147 | AAANAIRVY | "ATP-binding cassette sub-family B member 10, mitochondrial" | Serum | 947.51886 | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11148 | AAATRTTSF | BTB/POZ domain-containing adapter for CUL3-mediated RhoA degradation protein 3 | Serum | 924.46649 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11149 | AAATSVHVV | Rho GTPase-activating protein 17 | Serum | NA | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11150 | AAEEGLREL | Death-associated protein kinase 3 | Serum | 986.50327 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11152 | AAHSRVHEL | Kinesin-like protein KIF26A | Serum | 1018.5308 | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11153 | AAIVARHTY | Thioredoxin-interacting protein | Serum | NA | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11154 | AAKKPPVTF | Tripartite motif-containing protein 29 | Serum | 957.56475 | LC-MS | Melanoma | "Present in 4 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11155 | AAKSAALQV | Proline-rich protein PRCC | Serum | 857.49707 | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11156 | AAKSDLHEV | Mitochondrial Rho GTPase 1 | Serum | NA | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11157 | AAKVPGNQA | Chromodomain-helicase-DNA-binding protein 8 | Serum | 854.46102 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11158 | AALGTDKEL | Isoform B-delta of Transcription factor 4 | Serum | NA | LC-MS | Melanoma | "Present in 4 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11159 | AAMSVAKRV | Pre-mRNA-splicing factor ATP-dependent RNA helicase PRP16 | Serum | 931.52732 | LC-MS | Melanoma | "Present in 4 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11160 | AAMSVAQRV | Putative pre-mRNA-splicing factor ATP-dependent RNA helicase DHX15 | Serum | 931.49094 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11161 | AANDKLKKM | Cytoplasmic dynein 1 heavy chain 1 | Serum | 1017.5641 | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11162 | AANGVIHML | Stabilin-1 | Serum | NA | LC-MS | Melanoma | "Present in 4 cancer samples out of 8 cancer samples. ,Present in 4 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11163 | AANPNGRYY | Fibrinogen beta chain | Serum | 1024.4726 | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11164 | AAQAHTREL | E3 ubiquitin-protein ligase BRE1B | Serum | 995.51484 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11165 | AAQEAVKLY | Heterogeneous nuclear ribonucleoprotein Q | Serum | 991.53385 | LC-MS | Melanoma | "Present in 5 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11166 | AAQETERLL | BAG family molecular chaperone regulator 5 | Serum | NA | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11167 | AAQSEAKVV | MICOS complex subunit MIC60 | Serum | 901.4869 | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11168 | AARAEAREI | Leucine-rich repeat flightless-interacting protein 1 | Serum | 985.53049 | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11169 | AARSQLETY | Protein Hook homolog 3 | Serum | 1037.5142 | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11170 | AASAAQREL | Talin-1 | Serum | 915.47739 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11171 | AASEEARSL | cAMP-dependent protein kinase type I-alpha regulatory subunit | Serum | 932.45632 | LC-MS | Melanoma | "Present in 6 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11172 | AASEQARQL | NF-kappa-B essential modulator | Serum | 972.49886 | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11173 | AASGALRNL | Catenin delta-1 | Serum | 871.48756 | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11174 | AASGGLRQV | Tyrosine-protein kinase Fes/Fps | Serum | 857.47191 | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11175 | AASGSARAF | Transcription factor SOX-18 | Serum | 836.41407 | LC-MS | Melanoma | "Present in 6 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11176 | AASKDPREV | Histone-lysine N-methyltransferase EHMT1 | Serum | NA | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11178 | AASPVGKRL | Lysine-specific demethylase 3B | Serum | NA | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11179 | AASQINRAY | ER membrane protein complex subunit 2 | Serum | 992.50394 | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11180 | AASSIQRVL | Dol-P-Glc:Glc(2)Man(9)Glcc(2)-PP-Dol alpha-1AG10A_HUMAN | Serum | 943.54508 | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11181 | AASSLKKQY | AT-rich interactive domain-containing protein 1A | Serum | 994.54475 | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11182 | AASTSARNY | Mitotic spindle assembly checkpoint protein MAD1 | Serum | 939.44101 | LC-MS | Melanoma | "Present in 7 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11183 | AATAVTQAL | Talin-1 | Serum | 844.46543 | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11184 | AATDHSNQL | HEAT repeat-containing protein 5B | Serum | 955.43592 | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11185 | AATDIARQV | Septin-6 | Serum | 943.50869 | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11186 | AATEVSKEL | A-kinase anchor protein 12 | Serum | 946.49713 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11187 | AATGRLLLL | Amyloid-like protein 2 (Fragment) | Serum | 926.5913 | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11188 | AATKIINEV | Mesencephalic astrocyte-derived neurotrophic factor | Serum | 957.5495 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11189 | AATPAVRTV | Polyadenylate-binding protein 1 | Serum | 884.50797 | LC-MS | Melanoma | "Present in 5 cancer samples out of 8 cancer samples. ,Present in 4 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11190 | AATRWAKKI | 60S ribosomal protein L14 | Serum | 1043.624 | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11191 | AATSATHEL | Lipopolysaccharide-responsive and beige-like anchor protein | Serum | 899.43486 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11192 | AATSNLKKL | Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform | Serum | 944.56548 | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11193 | AATSNVHMV | KN motif and ankyrin repeat domain-containing protein 2 | Serum | NA | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11194 | AATVTKKTY | Chromodomain-helicase-D-binding protein 4 | Serum | NA | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11195 | AAVDRTTEL | Protein bicaudal D homolog 2 | Serum | 974.50327 | LC-MS | Melanoma | "Present in 4 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11196 | AAVGQAAHL | Cytochrome P450 1B1 | Serum | 836.45045 | LC-MS | Melanoma | "Present in 4 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11197 | AAVKATQTL | ELM2 and SANT domain-containing protein 1 | Serum | 901.52328 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11198 | ADSVGHHL | Transportin-1 | Serum | NA | LC-MS | Melanoma | "Present in 4 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11199 | AEALPKQSV | Transcription factor BTF3 | Serum | NA | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11200 | AEDKDTPAL | E3 ubiquitin-protein ligase HUWE1 | Serum | 958.46074 | LC-MS | Melanoma | "Present in 4 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11201 | AEDRPSEQL | Histone deacetylase 7 | Serum | 1043.4884 | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11203 | AEGTLSKKL | R-binding protein 34 | Serum | NA | LC-MS | Melanoma | "Present in 4 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11204 | AEKAVTKEEF | 40S ribosomal protein SA | Serum | 1150.587 | LC-MS | Melanoma | "Present in 4 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11205 | AEKAYHEQL | Tubulin alpha-1B chain | Serum | 1087.5298 | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11207 | AENKDEIAL | X-ray repair cross-complementing protein 5 | Serum | 1001.5029 | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11208 | AEQESARQL | Plectin | Serum | 1030.5043 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11209 | AEQRGENAL | Keratin | Serum | 986.47812 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11210 | AESGAKEEL | Myristoylated alanine-rich C-kinase substrate | Serum | 932.44509 | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11211 | AESGRGQVM | Interleukin-32 | Serum | NA | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11212 | AETGKPVTL | Cytochrome P450 3A4 | Serum | 914.5073 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11213 | AEVKKPAAA | Serpin H1 | Serum | NA | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11215 | AGHLSTAQY | Eukaryotic translation initiation factor 4 gamma 1 | Serum | 946.45084 | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11216 | AGNPMVKSV | Protein PRRC1 | Serum | NA | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11217 | AGTAVVGVVL | Ephrin type-B receptor 4 | Serum | 884.53312 | LC-MS | Melanoma | "Present in 4 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11218 | AGTSYRNVL | CASP8 and FADD-like apoptosis regulator | Serum | NA | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11219 | AHAKSSVAL | Mediator of R polymerase II transcription subunit 23 | Serum | 882.49232 | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11220 | AIASTLVHK | Poly(A) polymerase alpha | Serum | NA | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11221 | AILDKTTNK | R-binding motif | Serum | 1002.571 | LC-MS | Melanoma | "Present in 4 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11222 | AINKPLSEK | Cytochrome P450 1A2 | Serum | 998.57605 | LC-MS | Melanoma | "Present in 4 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11223 | AINKPLSEKM | Cytochrome P450 1A3 | Serum | NA | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11224 | AIVDKVPSV | Coatomer subunit gamma-1 | Serum | NA | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11225 | AIYGTRKFK | Macrophage-expressed gene 1 protein | Serum | 1082.6237 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11226 | ALADGVQKV | Apolipoprotein L1 | Serum | 899.50763 | LC-MS | Melanoma | "Present in 8 cancer samples out of 8 cancer samples. ,Present in 4 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11227 | ALASHLIEA | EH domain-containing protein 2 | Serum | 923.50763 | LC-MS | Melanoma | "Present in 8 cancer samples out of 8 cancer samples. ,Present in 4 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11228 | ALATLIHQV | COP9 signalosome complex subunit 7a | Serum | NA | LC-MS | Melanoma | "Present in 6 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11230 | ALISNSHQL | Transcription factor Maf | Serum | 981.52434 | LC-MS | Melanoma | "Present in 8 cancer samples out of 8 cancer samples. ,Present in 4 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11231 | ALKNPPINTK | Actin-related protein 2/3 complex subunit 5 | Serum | 1094.6448 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11232 | ALKTGIVAK | Uncharacterized protein C19orf43 | Serum | 899.5804 | LC-MS | Melanoma | "Present in 4 cancer samples out of 8 cancer samples. ,Present in 4 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11233 | ALNDHHVYL | Fructose-bisphosphate aldolase B | Serum | 1080.5352 | LC-MS | Melanoma | "Present in 8 cancer samples out of 8 cancer samples. ,Present in 4 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11234 | ALPEKVVNK | AT-rich interactive domain-containing protein 4B (Fragment) | Serum | NA | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11235 | ALQEMVHQV | NA | Serum | 1053.5277 | LC-MS | Melanoma | "Present in 7 cancer samples out of 8 cancer samples. ,Present in 4 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11236 | ALRDVRQQY | NA | Serum | 1147.6098 | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11237 | ALSDHHIYL | Fructose-bisphosphate aldolase A | Serum | 1067.54 | LC-MS | Melanoma | "Present in 8 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11238 | ALSPSLKNK | Probable helicase senataxin | Serum | NA | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11239 | ALSSVGSPK | CD109 antigen | Serum | NA | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11240 | ALSTALSEK | Prelamin-A/C | Serum | NA | LC-MS | Melanoma | "Present in 5 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11241 | ALYAQARAK | Inter-alpha-trypsin inhibitor heavy chain H2 | Serum | 990.56106 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11242 | ALYARRRSY | Bax inhibitor 1 | Serum | 1154.6309 | LC-MS | Melanoma | "Present in 4 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11243 | ALYHNNEEK | SPRY domain-containing protein 7 | Serum | NA | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11244 | ALYSGVHKK | SAM and SH3 domain-containing protein 1 | Serum | 1001.5658 | LC-MS | Melanoma | "Present in 4 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11245 | AMSERALAQK | Protein SON | Serum | 1103.5757 | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11247 | ANTQVVREV | Rho GTPase-activating protein 1 | Serum | 1014.5458 | LC-MS | Melanoma | "Present in 0 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11248 | APAPAAHVA | Y-box-binding protein 3 | Serum | 803.42899 | LC-MS | Melanoma | "Present in 5 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11249 | APAPKPEAA | Zinc finger protein 316 | Serum | 850.45487 | LC-MS | Melanoma | "Present in 5 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11250 | APAQRAQSL | KN motif and ankyrin repeat domain-containing protein 2 | Serum | 940.50903 | LC-MS | Melanoma | "Present in 0 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11251 | APHRPAPAL | Gelsolin | Serum | NA | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11252 | APKATPVAA | Microtubule-associated protein 1S | Serum | 824.4756 | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11253 | APKRPPSAF | High mobility group protein B2 | Serum | NA | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11254 | APRAGRDYSA | "Keratin, type I cytoskeletal 20" | Serum | 1062.5207 | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11256 | APRQPGLMA | Coiled-coil-helix-coiled-coil-helix domain-containing protein 2 | Serum | 939.49602 | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11257 | APRTVALTA | HLA class II histocompatibility antigen | Serum | 898.52362 | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11258 | APSQQRQQI | Pre-mRNA-processing-splicing factor 8 | Serum | NA | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11259 | APSVGIKAA | Proteasome subunit alpha type-2 | Serum | NA | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11260 | APYRTQSSA | RNA-binding protein 14 | Serum | 979.47231 | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11261 | AQKAVGKDNF | Dihydropyrimidinase-related protein 4 | Serum | NA | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11262 | AQNAKVIEK | UPF0428 protein CXorf56 | Serum | 999.57129 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11263 | AQNAVRLHY | Catenin beta-1 | Serum | 1070.5621 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11264 | AQNEPLTQK | NA | Serum | 1027.5298 | LC-MS | Melanoma | "Present in 4 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11265 | AQQDLQSKF | Kinectin | Serum | NA | LC-MS | Melanoma | "Present in 0 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11266 | AQQKNLEGY | Septin-7 | Serum | 1049.5142 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11267 | AQQRAQAAL | Laminin subunit beta-2 | Serum | NA | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11268 | AQRDAQELY | Annexin A11 | Serum | NA | LC-MS | Melanoma | "Present in 0 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11270 | ASIGNAQKL | PDZ and LIM domain protein 1 | Serum | NA | LC-MS | Melanoma | "Present in 0 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11271 | ASLGHILVF | Phospholemman | Serum | 955.5491 | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11272 | ASLVGQTSPK | Nucleolar protein 58 | Serum | NA | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11273 | ASNPRQAAY | 5'-3' exoribonuclease 2 | Serum | NA | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11274 | ASSGALRSY | DENN domain-containing protein 1C | Serum | NA | LC-MS | Melanoma | "Present in 4 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11275 | ASSPVLRQM | Nuclear receptor coactivator 1 | Serum | 987.51715 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11276 | ASSSFQHEM | Integrin alpha-D | Serum | 1022.4127 | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11277 | ASVALLEASL | Protein phosphatase 1 regulatory inhibitor subunit 16B | Serum | 972.54916 | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11278 | ASVDKVLEL | Heterogeneous nuclear ribonucleoprotein D-like | Serum | NA | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11280 | ASYGVSKGK | Heterogeneous nuclear ribonucleoprotein U (Fragment) | Serum | NA | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11282 | ATALPTGTSK | E3 ubiquitin-protein ligase SIAH1 | Serum | 945.51311 | LC-MS | Melanoma | "Present in 0 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11283 | ATANQIILK | Muscleblind-like protein 2 (Fragment) | Serum | 970.58113 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11284 | ATAPAPTAHK | Histone H1x | Serum | NA | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11285 | ATAQGRYY | Lysosomal alpha-mannosidase | Serum | NA | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11286 | ATAQNIMNPK | Ankyrin repeat and SAM domain-containing protein 4B | Serum | 1086.5492 | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11287 | ATDIPSSQK | Adenomatous polyposis coli protein | Serum | NA | LC-MS | Melanoma | "Present in 4 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11288 | ATDKSFVEK | Myosin-9 | Serum | 1023.5237 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11289 | ATDLTREVY | E3 ubiquitin-protein ligase UBR2 | Serum | 1066.5295 | LC-MS | Melanoma | "Present in 0 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11290 | ATEQPLTAK | Nucleotide exchange factor SIL1 | Serum | 957.51311 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11291 | ATEYKNEEY | YTH domain-containing protein 1 | Serum | 1145.4877 | LC-MS | Melanoma | "Present in 0 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11292 | ATHGRFLEI | Fatty acid synthase | Serum | 1042.556 | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11293 | ATHTAFVAK | "Lamina-associated polypeptide 2, isoform alpha" | Serum | 944.50797 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11294 | ATHTGLSTF | Perilipin-4 | Serum | 933.4556 | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11295 | ATKSPTAEEY | Probable G-protein coupled receptor 116 | Serum | 1095.5084 | LC-MS | Melanoma | "Present in 0 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11296 | ATNDSVVADK | Proteasome subunit beta type-10 | Serum | NA | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11297 | ATSAFQTQK | Retinoblastoma-associated protein | Serum | NA | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11298 | ATSNVHMVK | KN motif and ankyrin repeat domain-containing protein 2 | Serum | NA | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11299 | ATTHEIMGPK | Phosphatidylinositol-binding clathrin assembly protein | Serum | NA | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11300 | ATTTVMNPK | Integrin beta-2 | Serum | NA | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11301 | ATVTPSPVK | Nuclear ubiquitous casein and cyclin-dependent kinase substrate 1 | Serum | NA | LC-MS | Melanoma | "Present in 4 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11302 | ATYAGVGANK | ALS2 C-terminal-like protein | Serum | NA | LC-MS | Melanoma | "Present in 6 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11303 | ATYHGSFSTK | Collagen alpha-3(VI) chain | Serum | NA | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11304 | ATYREGMTK | Proteasome subunit beta type-6 | Serum | 1055.507 | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11305 | ATYSVGMQK | Rhophilin-2 | Serum | NA | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11306 | AVAAVAARR | Neutral alpha-glucosidase AB | Serum | 883.53518 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11307 | AVADSVLTK | E3 ubiquitin-protein ligase RNF213 | Serum | NA | LC-MS | Melanoma | "Present in 4 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11308 | AVAHALTEK | T-complex protein 1 subunit gamma | Serum | NA | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11309 | AVAIKAMAK | Eukaryotic translation initiation factor 5A-1 | Serum | 901.54191 | LC-MS | Melanoma | "Present in 4 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11310 | AVALPLQTK | Pleiotropic regulator 1 | Serum | 939.57532 | LC-MS | Melanoma | "Present in 6 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11311 | AVASSVVKQK | Histone deacetylase 7 | Serum | NA | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11312 | AVDATLRKK | Protein AAR2 homolog | Serum | 1000.6029 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11314 | AVGPHLTAK | Tumor necrosis factor alpha-induced protein 8-like protein 1 | Serum | 892.51305 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11315 | AVKPLGPTA | Phosphatidylinositol 4-phosphate 5-kinase type-1 gamma | Serum | 852.5069 | LC-MS | Melanoma | "Present in 5 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11317 | AVMGNPKVK | Hemoglobin subunit beta | Serum | 942.53207 | LC-MS | Melanoma | "Present in 5 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11318 | AVNAHSNILK | MICOS complex subunit MIC60 | Serum | 1065.5931 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11319 | AVQKAIAHY | Interferon-induced guanylate-binding protein 1 | Serum | 999.55016 | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11321 | AVTKYTSSK | Histone H2B type 1-C/E/F/G/I | Serum | NA | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11322 | AVTSVAKVV | "Interferon alpha-inducible protein 27, mitochondrial" | Serum | 872.53312 | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11323 | AVTTTVTGAK | Perilipin-2 | Serum | NA | LC-MS | Melanoma | "Present in 5 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11325 | AVYENAREK | Integrator complex subunit 8 | Serum | 1078.5407 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11326 | AVYETPTAH | Toll-interacting protein | Serum | 987.46616 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11327 | AVYGGFKSK | Alcohol dehydrogenase 1B | Serum | 955.51272 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11328 | AVYSHVIQK | L-serine dehydratase/L-threonine deaminase | Serum | 1043.5764 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11330 | DAAAKALRI | Double-stranded RNA-binding protein Staufen homolog 1 | Serum | 927.55016 | LC-MS | Melanoma | "Present in 7 cancer samples out of 8 cancer samples. ,Present in 4 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11331 | DAAEIRLV | Nucleolin | Serum | NA | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11332 | DAAELAQHV | Zinc finger protein 580 | Serum | NA | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11333 | DAAHAQTEV | Mitochondrial import receptor subunit TOM70 | Serum | 940.42502 | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11334 | DAAQRSQHI | E3 ubiquitin-protein ligase makorin-1 | Serum | 1024.505 | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11335 | DAASYVRKV | cAMP-dependent protein kinase type I-alpha regulatory subunit | Serum | 1007.54 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11336 | DAAYMNKV | "Keratin, type II cytoskeletal 5" | Serum | NA | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 4 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11337 | DADSRAATV | SH3 and multiple ankyrin repeat domains protein 3 | Serum | 904.42502 | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11338 | DAEMTTRMV | Proteasome subunit beta type-10 | Serum | 1052.4631 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11339 | DAENAMRYI | Nuclear cap-binding protein subunit 2 | Serum | NA | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11340 | DAGGHNVTI | 26S proteasome non-ATPase regulatory subunit 1 | Serum | 882.41954 | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11341 | DAHIYLNHI | Thymidylate synthase | Serum | 1094.5509 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11343 | DAHRSHPFI | Coatomer subunit epsilon | Serum | 1078.5308 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11344 | DAHSNLASI | UDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunit | Serum | 926.44576 | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11345 | DAIRQSNQI | NF-kappa-B essential modulator | Serum | 1043.536 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11346 | DAIRTSEI | Uncharacterized protein C1orf43 | Serum | 903.46616 | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11347 | DAIRVTKTV | WD repeat-containing protein 11 (Fragment) | Serum | 1001.5869 | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11348 | DAKEIKDAI | Annexin A6 | Serum | 1001.5393 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11349 | DAKKEMASL | Protein diaphanous homolog 1 | Serum | 991.50083 | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11350 | DAKLDKAQI | Heat shock 70 kDa protein 1A/1B | Serum | 1000.5553 | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11351 | DAKLDKSQI | Heat shock cognate 71 kDa protein | Serum | 1016.5502 | LC-MS | Melanoma | "Present in 4 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11352 | DAKQLTTTI | Enhancer of filamentation 1 | Serum | 989.53933 | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11353 | DALDKIRLI | Endoplasmin | Serum | 1055.6339 | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11354 | DALDVANKI | 60S ribosomal protein L23a | Serum | NA | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11355 | DALKEKVI | S-adenosylmethionine synthase isoform type-2 | Serum | 914.54368 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11356 | DALLKFSHI | Bax inhibitor 1 | Serum | 1042.5811 | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11357 | DANNAKAVV | CD81 antigen | Serum | NA | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11358 | DANTQVHTL | Formin-like protein 2 | Serum | 997.48287 | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11359 | DAPHPLSKI | Ornithine decarboxylase antizyme 2 | Serum | 976.53418 | LC-MS | Melanoma | "Present in 4 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11360 | DAPHPPLKI | Ornithine decarboxylase antizyme 1 | Serum | 986.55492 | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11361 | DAPIVAHL | "Carnitine O-palmitoyltransferase 1, liver isoform" | Serum | NA | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11362 | DAPMTPKQI | "Additional sex combs like 1 (Drosophila), isoform CRA_d" | Serum | NA | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11363 | DAQMARKV | Rap guanine nucleotide exchange factor 2 | Serum | NA | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11364 | DARKTLDSV | Prelamin-A/C | Serum | 1003.5298 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11366 | DATQRQLTV | Unconventional myosin-Ia | Serum | 1030.5407 | LC-MS | Melanoma | "Present in 6 cancer samples out of 8 cancer samples. ,Present in 4 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11367 | DAVKALKA | Deoxyribose-phosphate aldolase | Serum | NA | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11368 | DAVKILKL | Probable helicase senataxin | Serum | NA | LC-MS | Melanoma | "Present in 7 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11369 | DAVTQETRI | Protein TALPID3 | Serum | 1031.5247 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11370 | DAYALNHTL | POU domain class 2-associating factor 1 | Serum | 1016.4927 | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11371 | DAYELKHAL | Annexin A5 | Serum | 1058.5397 | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11372 | DAYTKKELI | Talin-1 | Serum | 1079.5863 | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11373 | DEKKMEKL | Talin-1 | Serum | NA | LC-MS | Melanoma | "Present in 0 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11374 | DEQNRKALY | Palmdelphin | Serum | 1135.5622 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11375 | DESGPSIVH | "Actin, cytoplasmic 2" | Serum | 939.42977 | LC-MS | Melanoma | "Present in 0 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11376 | DETLIHSH | CTD nuclear envelope phosphatase 1 | Serum | NA | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11377 | DETTVRKL | Protein ENL | Serum | NA | LC-MS | Melanoma | "Present in 0 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11378 | DFLAEGGGVR | Fibrinogen alpha chain | Serum | 1019.5036 | LC-MS | Melanoma | "Present in 8 cancer samples out of 8 cancer samples. ,Present in 4 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11379 | DGKTEVHKI | Protein FAM160B1 | Serum | 1025.5506 | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11380 | DGPKKTISV | Prolow-density lipoprotein receptor-related protein 1 | Serum | 943.53385 | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11381 | DGQLKSLTI | DnaJ homolog subfamily B member 6 | Serum | 973.54441 | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11382 | DGQLKSVTI | DnaJ homolog subfamily B member 2 | Serum | 959.52876 | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11383 | DGYEQAARV | T-complex protein 1 subunit epsilon | Serum | NA | LC-MS | Melanoma | "Present in 4 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11384 | DHFASVHSV | Intraflagellar transport protein 25 homolog | Serum | 997.46174 | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11385 | DIVMTQSPD | Ig kappa chain V-IV region STH (Fragment) | Serum | NA | LC-MS | Melanoma | "Present in 8 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11386 | DKVIPLAIPQ | Alcohol dehydrogenase 1A | Serum | NA | LC-MS | Melanoma | "Present in 4 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11387 | DPKSADTQSI | "Glycerol-3-phosphate dehydrogenase, mitochondrial" | Serum | 1060.5037 | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11388 | DPLKATHAV | Collagen type IV alpha-3-binding protein | Serum | NA | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11389 | DPLQAKKV | Transcription factor 12 | Serum | NA | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11390 | DPMKARVV | Signal recognition particle 9 kDa protein | Serum | NA | LC-MS | Melanoma | "Present in 5 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11391 | DPQQVVHRV | Coatomer subunit zeta-1 | Serum | 1076.5727 | LC-MS | Melanoma | "Present in 4 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11392 | DPYEVSYRI | Protein BTG2 | Serum | 1140.5451 | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11393 | DPYVRKTAA | AP-2 complex subunit beta | Serum | 1019.54 | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11395 | DSYTLHKI | 26S protease regulatory subunit 8 | Serum | NA | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11396 | DTVLVHRV | Lysine-specific histone demethylase 1A | Serum | NA | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11397 | DVLQVHKV | Nck-associated protein 1-like | Serum | NA | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11398 | DVRQQYESV | Vimentin | Serum | 1122.5306 | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11399 | EAAEPKEV | Leucine-rich repeat flightless-interacting protein 1 | Serum | NA | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11400 | EAFGNAKTV | Myosin-9 | Serum | NA | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11403 | EAGSSRSQEI | CBP80/20-dependent translation initiation factor | Serum | 1062.4942 | LC-MS | Melanoma | "Present in 4 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11404 | EAHRIQQI | Flotillin-2 | Serum | 993.53558 | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11405 | EAKTHEAQI | Myosin-9 | Serum | 1025.5142 | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11406 | EALEAARI | 60S ribosomal protein L10 | Serum | NA | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11407 | EALGNVRTV | "ATP-binding cassette sub-family B member 8, mitochondrial" | Serum | 957.52434 | LC-MS | Melanoma | "Present in 4 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11410 | EATDYLRNL | DST protein | Serum | NA | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11411 | EAYLGKKV | 78 kDa glucose-regulated protein | Serum | 906.51747 | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11412 | EAYLGKTV | Heat shock cognate 71 kDa protein | Serum | NA | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11413 | EDSDRAIEGR | Prothrombin | Serum | 1146.5265 | LC-MS | Melanoma | "Present in 8 cancer samples out of 8 cancer samples. ,Present in 4 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11414 | EEAEIIRKY | Poly [ADP-ribose] polymerase 1 | Serum | NA | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11415 | EEKTISAKY | Myosin-9 | Serum | 1067.5499 | LC-MS | Melanoma | "Present in 4 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11416 | EELLRFSN | Protein AMBP | Serum | 1006.5084 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11417 | EELQQKVSY | Signal transducer and activator of transcription 3 | Serum | 1122.5557 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11418 | EEMEAKQNL | Isoform 4 of Myosin-11 | Serum | NA | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11419 | EENKLVKKI | Septin-7 | Serum | 1099.6601 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11420 | EERVINEEY | Histone-binding protein RBBP4 | Serum | 1179.5408 | LC-MS | Melanoma | "Present in 0 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11421 | EESDLSRQY | General transcription factor 3C polypeptide 1 | Serum | 1125.4938 | LC-MS | Melanoma | "Present in 4 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11422 | EESEQIKTL | "Keratin, type II cytoskeletal 7" | Serum | 1075.5397 | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11423 | EEVHDLERKY | Nucleosome assembly protein 1-like 1 | Serum | NA | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11425 | EGKLTHKI | NudC domain-containing protein 3 | Serum | NA | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11427 | EHSKPVVL | Nesprin-2 | Serum | 907.51272 | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11428 | EHVKEVQQL | Ribosome-binding protein 1 | Serum | 1108.5877 | LC-MS | Melanoma | "Present in 0 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11429 | ERAGVVREL | RNA polymerase II subunit A C-terminal domain phosphatase | Serum | 1027.5774 | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11432 | ERSDLIKHY | Zinc finger protein 436 | Serum | 1159.5986 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11434 | ETATLRSGY | Endoplasmin | Serum | NA | LC-MS | Melanoma | "Present in 4 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11435 | ETEKMIEKY | "Spectrin beta chain, non-erythrocytic 1" | Serum | NA | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11436 | ETTSTTLRY | Cytochrome P450 2E1 | Serum | 1070.5244 | LC-MS | Melanoma | "Present in 7 cancer samples out of 8 cancer samples. ,Present in 4 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11437 | EVAEVSRQY | "Phospholipase B1, membrane-associated" | Serum | 1079.5247 | LC-MS | Melanoma | "Present in 4 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11438 | EVIQGDVKSY | Xin actin-binding repeat-containing protein 2 | Serum | 1136.5714 | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11439 | EVQLVESGG | Ig gamma-1 chain C region | Serum | 916.45018 | LC-MS | Melanoma | "Present in 6 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11440 | EVQLVESGGD | Ig heavy chain V-III region DOB | Serum | 1031.4771 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11441 | EVVDKINQV | Nesprin-2 | Serum | 1042.5659 | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11442 | EVYAGSHQY | Golgi resident protein GCP60 | Serum | 1052.4563 | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11443 | FAKEGHSSL | Solute carrier organic anion transporter family member 1B1 | Serum | 974.48214 | LC-MS | Melanoma | "Present in 6 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11444 | FAQDQEHQV | C-Jun-amino-terminal kinase-interacting protein 4 | Serum | 1100.4887 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11446 | FENKFAVET | Integral membrane protein 2B (Fragment) | Serum | 1083.5237 | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11447 | FLAEGGG | Fibrinogen alpha chain | Serum | 649.30714 | LC-MS | Melanoma | "Present in 7 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11448 | FLAEGGGVR | Fibrinogen alpha chain | Serum | 904.47667 | LC-MS | Melanoma | "Present in 8 cancer samples out of 8 cancer samples. ,Present in 4 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11449 | FNDPNAKEM | Zinc finger RNA-binding protein | Serum | 1064.4597 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11450 | FRHDKRVYL | Pre-mRNA-processing-splicing factor 8 | Serum | 1232.6778 | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11451 | FVIETARQL | Interferon regulatory factor 2-binding protein-like | Serum | 1075.6026 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11453 | GATPHLRNL | Proteasome assembly chaperone 4 | Serum | 977.54066 | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11456 | GDEELLRFSN | Protein AMBP | Serum | 1178.5568 | LC-MS | Melanoma | "Present in 5 cancer samples out of 8 cancer samples. ,Present in 4 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11459 | GEAAKSVKL | Protein S100-A14 | Serum | 901.52328 | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11460 | GEASRLAHY | Histone H2B type 1-C/E/F/G/I | Serum | 1002.4883 | LC-MS | Melanoma | "Present in 7 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11461 | GEDVETSKKW | Endothelial differentiation-related factor 1 | Serum | 1177.5615 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11462 | GEEKEAATL | Hepatoma-derived growth factor | Serum | 946.46074 | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11463 | GEEQNKEAL | 14-3-3 protein epsilon | Serum | 1016.4775 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11466 | GEGDGIIREL | Aldehyde oxidase | Serum | 1057.5404 | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11467 | GELAKHAV | Histone H2B type 1-C/E/F/G/I | Serum | NA | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11468 | GELTGEVRM | Filamin-C | Serum | NA | LC-MS | Melanoma | "Present in 4 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11469 | GEQEDRPGL | Lymphocyte-specific protein 1 | Serum | NA | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11472 | GESSGKNVTL | 60S ribosomal protein L4 | Serum | 990.49819 | LC-MS | Melanoma | "Present in 4 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11473 | GETGIGKSTL | Septin-10 | Serum | NA | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11474 | GETKAVKTV | Alpha-1B-glycoprotein | Serum | NA | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11475 | GETSTVEKL | NF-kappa-B inhibitor beta | Serum | NA | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11477 | GEVSARQEL | Elongation factor 2 | Serum | 987.49852 | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11486 | GIASSSIAAK | "Interferon alpha-inducible protein 27, mitochondrial" | Serum | NA | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11489 | GKAQMQSPA | Plasma kallikrein | Serum | 916.44365 | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11492 | GLEAIQRTPK | Beta-2-microglobulin | Serum | 1111.635 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11494 | GLYGQTTGK | GTP-binding protein SAR1b | Serum | NA | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11495 | GLYQKSAMK | Myosin-4 | Serum | 1024.5376 | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11496 | GLYQKSSLK | Myosin-13 | Serum | 1022.576 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11501 | GQHVATQHF | Glycosylphosphatidylinositol anchor attachment 1 protein | Serum | NA | LC-MS | Melanoma | "Present in 0 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11502 | GQLSVHTPK | Forkhead box protein P1 | Serum | NA | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11503 | GQQVTLTTH | Transmembrane protein 223 | Serum | 983.50361 | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11504 | GQRKPATSY | 60S ribosomal protein L28 | Serum | NA | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11505 | GQSKAVKVY | Chromodomain-helicase-DNA-binding protein 8 | Serum | NA | LC-MS | Melanoma | "Present in 0 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11506 | GQSSPQRSY | Pseudopodium-enriched atypical kinase 1 | Serum | NA | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11507 | GQTKVLTQK | Thioredoxin-interacting protein | Serum | 1001.5869 | LC-MS | Melanoma | "Present in 5 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11508 | GRIGQAIAR | Glyoxylate reductase/hydroxypyruvate reductase | Serum | 940.55665 | LC-MS | Melanoma | "Present in 6 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11509 | GRIGVITNR | "40S ribosomal protein S4, X isoform" | Serum | 984.58286 | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11510 | GRILSGVVTK | 40S ribosomal protein S11 | Serum | 1028.6342 | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11511 | GRLQGGLTAR | Galectin-4 | Serum | 1027.5887 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11512 | GRYGGETKV | Serine/arginine-rich splicing factor 7 | Serum | 965.49304 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11513 | GRYPEAQSV | DnaJ homolog subfamily C member 7 | Serum | 1005.488 | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11516 | GSYSSHISSK | Zinc finger E-box-binding homeobox 1 | Serum | 1051.4934 | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11517 | GTAEVELKK | Pyruvate kinase PKM | Serum | NA | LC-MS | Melanoma | "Present in 5 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11518 | GTAPAFKQK | "Myosin light chain kinase, smooth muscle" | Serum | NA | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11519 | GTDPTPQHY | Tyrosine-protein kinase Fyn | Serum | 1014.4407 | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11520 | GTDSHLVVKK | "Arf-GAP with Rho-GAP domain, ANK repeat and PH domain-containing protein 1" | Serum | 1082.6084 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11521 | GTFGGLGSK | Neuroblast differentiation-associated protein AHNAK | Serum | NA | LC-MS | Melanoma | "Present in 5 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11522 | GTHKVTVLF | Filamin-A | Serum | 1000.5706 | LC-MS | Melanoma | "Present in 5 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11523 | GTHSHGLFK | Cytochrome P450 3A4 | Serum | 982.49846 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11524 | GTLNQPLTK | Activating signal cointegrator 1 | Serum | NA | LC-MS | Melanoma | "Present in 4 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11525 | GTMTGMLYK | Mitochondrial import inner membrane translocase subunit Tim23 | Serum | 1000.4722 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11526 | GTNTTGISEK | Interferon-induced protein 44 | Serum | NA | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11527 | GTQPIKVSW | Titin | Serum | NA | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11528 | GTYAHTVNR | Intestinal-type alkaline phosphatase | Serum | 1017.4992 | LC-MS | Melanoma | "Present in 4 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11529 | GTYDAKVKK | Tubulin polymerization-promoting protein family member 3 | Serum | 1008.5604 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11530 | GTYQPLSTR | WD repeat-containing protein 46 | Serum | 1021.5193 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11531 | GTYSKIMNH | Rho-associated protein kinase 1 | Serum | 1049.4964 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11532 | GTYVKPLSNK | Peroxisomal acyl-coenzyme A oxidase 1 | Serum | 1105.6132 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11533 | GTYVSSVPR | "HLA class II histocompatibility antigen, DO alpha chain" | Serum | 964.49779 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11534 | GVADKILKK | N-myc-interactor | Serum | 970.61752 | LC-MS | Melanoma | "Present in 7 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11535 | GVANALAHK | Hemoglobin subunit beta | Serum | 879.49265 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 4 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11536 | GVAPGTSVK | "Phosphoenolpyruvate carboxykinase, cytosolic [GTP]" | Serum | NA | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11537 | GVGPIRKV | Golgi-associated PDZ and coiled-coil motif-containing protein | Serum | NA | LC-MS | Melanoma | "Present in 4 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11538 | GVHGGLINK | Profilin-1 | Serum | 893.5083 | LC-MS | Melanoma | "Present in 6 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11539 | GVHTVHVTF | Filamin-A | Serum | 995.51886 | LC-MS | Melanoma | "Present in 1 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11540 | GVVQPGRSL | Ig heavy chain V-III region KOL | Serum | 911.51886 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11541 | GVYESGPRK | Phosphoinositide 3-kinase adapter protein 1 | Serum | NA | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11542 | GVYGGSVHEA | Cytosolic non-specific dipeptidase | Serum | NA | LC-MS | Melanoma | "Present in 8 cancer samples out of 8 cancer samples. ,Present in 2 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11543 | HAAAYRNAL | "Cytochrome b-c1 complex subunit 2, mitochondrial" | Serum | 985.50936 | LC-MS | Melanoma | "Present in 2 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11544 | HAAELIKTV | Programmed cell death 6-interacting protein | Serum | 980.56548 | LC-MS | Melanoma | "Present in 3 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples." | 26992070 |
CancerPDF_ID11545 | HAAERMNQL | "TRAF and TNF receptor associated protein, isoform CRA_b" | Serum | 1068.5135 |